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Abstract 
Cancer is a highly mutating disease that quickly develops resistance to chemotherapies 
and has a high rate of relapse. If detected early, the survival rate is greater than 90% for 
most cancers; however if diagnosed during late, metastatic stages survival rate falls 
sharply to only 10%. Most cancer therapy is delivered systemically with no targeting 
specificity, which leads to high accumulation in healthy tissue and eventual toxicity. 
The high toxicity caused by current chemotherapeutics is a key limiting factor in 
complete eradication of tumors. Another key limiting factor is the development of 
resistive tumors. A large number of patients undergo multiple rounds of chemotherapy 
and surgery with the eventual progression into terminal stage cancer due to the 
development of resistive tumors. 
Phosphatidylserine (PS) composes 8 -15% of the total phospholipids that make 
up the plasma membrane of a mammalian cells. In normal, healthy cells, PS is 
asymmetrical and only expressed on the inner leaflet of the membrane. In apoptotic 
cells, PS is exposed on the extracellular surface of the membrane as an “eat me” signal 
for immune cells such as macrophages to initiate immune suppressive clearance. Viable 
cancer cells use PS in a similar manner by expressing it on the external leaflet of the 
plasma membrane along with other “don’t eat me” signals to promote an 
immunosuppressive environment without clearance. Due to this externalization, PS can 
be used as a specific target for biotechnology agents. Annexin V (ANXA5), a 
mammalian protein, specifically binds to PS in vitro as well as in vivo. ANXA5 can be 
use to target biotechnology agents, such as nanoparticles and molecular drugs, 
xvii 
specifically to the tumor. This thesis focuses on the use of the strong interaction 
between PS and ANXA5 in biotechnology agents for cancer.
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Chapter I: Introduction 
 Cancer 
Cancer is one of the most elusive and varied diseases; however within all cancers, there 
are six key hallmarks that assist in its survival and proliferation: 1) sustaining 
proliferative signaling, 2) evading growth suppressors, 3) activating invasion and 
metastasis, 4) enabling replicative immortality, 5) inducing angiogenesis, and 6) 
resisting cell death [1]. 
Cancer cells can sustain proliferation by either producing their own growth 
factors or stimulating the surrounding normal cells to produce tumor proliferative 
growth factors. In order to sustain their proliferative growth, cancer cells also have to 
hinder tumor suppressor signals such as retinoblastoma-associated (RB) and TP53 
proteins. The RB protein serves as a key gatekeeper by integrating extracellular signals 
with intracellular cell-cycle progression or inhibition. Many tumors have defects in their 
RB protein, thus losing the ability to check their growth feedback. Similar to the RB 
protein, TP53 also acts as a checkpoint gatekeeper; however most of its signals 
originate intracellularly. TP53 either activates or suppresses tumor growth based on the 
oxidative stress within the tumor and the degree of DNA mutations. TP53 is a common 
mutation among multiple tumors and in some cases is completely null, leading to 
uncontrollable growth [1-3]. 
The key to tumor progression is metastasis. Metastases can occur due to 
multiple cues including chemical, mechanical, and environmental. Initiation of 
metastasis is believed to occur via the epithelial to mesenchymal transition (EMT) in 
order to overcome anoikis, cell death as a result of detachment from the ECM. 
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Attachment to the ECM provides cells with pro-survival signals; however detachment 
for metastasis renders them venerable. Cancer cells down-regulate E-cadherin and up-
regulate N-cadherin surface receptors that allow for extravasation [1, 4, 5]. Along with 
EMT, cancer cells continue to proliferate further into an immortalized cycle due to 
significantly increased amounts of functional telomerase, which adds telomere to the 
ends of DNA strands to counteract the loss with time [1, 6]. 
Angiogenesis, sprouting of new vasculature, is also a key component to sustain 
tumor growth. In normal tissue, angiogenesis occurs primarily during development, 
wound healing, and the female reproductive cycle, which then gets switched off. 
However sprouting of neovessicles in tumors is continuously turned on, leading to the 
development of immature, leaky vasculature [1, 7]. 
 
Bladder Cancer 
Bladder cancer has one of the highest costs-to-patient ratios due to constant need for 
treatment of recurrent tumors. The current standard of care is a transurethral resection 
(TUR) followed by immunotherapy and Bacillus Calmette-Guerin (BCG) treatment 
intravesically. TUR surgery involves a cystoscope through the urethra to cut the bladder 
tumor, followed by cauterization. About 60-70% of bladder cancer patients have non-
muscle-invasive bladder cancer (NMIBC). For those treated with TUR followed with 
secondary intravesical treatment, 75% develop recurrence within 5 years [8]. Aside 
from surgery, two drugs have been FDA approved as an alternative, thiotepa and 
valrubicin; both are generally used against BCG resistive tumors. In conjunction with 
chemotherapy, electromotive administration (EMDA), which allows for deeper 
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penetration of drugs into the bladder urothelium, is used. A clinical study comparing the 
use of EMDA versus only chemotherapy provided promising results with an increase in 
5-year survival [9]. A hyperthermic heat-based approach using chemohyperthermia 
(CHT) has also been evaluated using epirubicin or mitomycin-c (MMC) in conjunction 
with microwaves (915 MHz) to increase bladder wall temperatures to greater than 41°C. 
Within two years, approximately half (56%) of the patients still had recurrence [8, 10]. 
 
Ovarian Cancer 
Most women are diagnosed with ovarian cancer during late, metastatic stages. About 5 - 
15% of women get ovarian cancer due to inherited factors with about 65% having 
BRAC1 and 35% having BRAC2 mutations [11]. If detected during early stages, the 5-
year survival rate is 90%; however this rate significantly falls to 19% if detected after 
metastasis. About 80% of patients with ovarian cancer will relapse after the first round 
of chemotherapy, with about 15 - 20% already developing platinum-resistive tumors. 
From these, about 10% of patients survive only a few months with eventual terminal 
cases [11]. 
 Due to a lack of an effective chemotherapy, clinical trials are underway using an 
anti-angiogenesis antibody, bevacizumab, with an overall 1 year survival rate of 58.6% 
[11, 12]. Another angiogenesis blockading therapy currently in clinical trials, 
pazopanib, had no survival increase but had increased risks of hypertension, 




Although improvement in treatment and diagnosis of breast cancer has caused a 
decrease in mortality rates, patients are still misdiagnosed or overdiagnosed in 10 - 65% 
of cases. If detected early on, patients have a 94% 5-year survival rate, which drops to 
only 10% once metastasis has occurred [14]. Breast cancer is one of the few cancers 
with mass diagnosis capabilities. Current diagnosis includes a yearly mammogram for 
women 40 – 54 years, followed by a biopsy and follow-up imaging if abnormalities are 
identified. One of the biggest problems with current diagnostic tools such as 
mammograms is their high false positive rates that result in patients often being 
overdiagnosed and overtreated, some leading to mortality due to radiation-induced 
tumors. A key reason for this misdiagnosis is the inability of a mammogram to 
distinguish a dense breast from a tumor.  
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Biotechnology Agents for Therapy 
Single-walled Carbon Nanotubes 
Carbon nanotubes are a promising tool for tumor therapy due to their high mechanical 
strength, strength-to-weight ratio, and high thermal conductivity [15]. It has been shown 
that about 84% of the heat generated within a nanotube is transmitted to its surrounding 
substrate [16, 17]. This property of thermal dispersion can be utilized for cancer 
ablative therapies to cause temperature-based homeostatic disruption. Once the 
temperature of a cell rises above 47°C, irreversible cell death by ablation occurs which 
is characterized by cell necrosis and tissue coagulation [18]. 
Nanotubes can be single-walled (SWCNTs) or multi-walled (MWCNTs) [19]. 
For a tumor ablative therapy, SWCNTs are preferred over MWCNTs due to the 
screening effect seen by the inner shells of MWCNTs. This electrostatic screening 
diminishes the incident field within the structure [20]. Studies have shown that the 
dominant power dissipation from MWCNTs is due to the outermost shell, which results 
in significantly decreased absorption compared to SWCNTs [20, 21]. 
 
Enzyme prodrug System 
An enzyme prodrug system is a multi-step process involving an enzyme delivered 
directly to the tumor followed by administration of a nontoxic prodrug, which is 
converted into a drug at the tumor [22, 23]. There are three main types of enzyme 
prodrug systems, gene-directed enzyme prodrug therapy (GDEPT), virus-directed 
enzyme prodrug therapy (VDEPT), and antibody-directed enzyme prodrug therapy 
(ADEPT) [22-24], each with advantages and disadvantages. One key advantage is the 
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ability to generate a toxic drug locally rather than systemic delivery of high doses of a 
cytotoxic drug, such as chemotherapy, that causes nonspecific tissue damage. Another 
key advantage is the bystander effect, which allows for small molecules to diffuse 
through the tissue to treat cancer cells with the enzyme bound as well as the 
surrounding cancer cells that do not have enzyme bound [22-24]. 
 GDEPT and VDEPT rely on the enzyme being produced by the cancer cells by 
delivering the gene directly, while ADEPT relies on a targeted enzyme delivered to the 
cancer. All are followed with systemic delivery of a prodrug substrate [22-24]. GDEPT 
has an increased risk for nontumor cell transfections and mutagenesis, while VDEPT 
has the risk of a virus reverting back to wild-type and undergoing uncontrollable 
replication [22-24]. VDEPT also usually targets only replicating cells within the tumor, 
which in turn leaves 80-94% of cells untargeted and untreated [22, 23]. ADEPT has the 
disadvantage of eliciting an immune response due to the use of a nonhuman enzyme as 
well as an uneven tumor distribution [22, 23, 25, 26]. 
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Biotechnology Agents for Imaging 
Gold Nanoparticles 
Gold nanoparticles have a significantly higher density compared to soft tissue, allowing 
them to generate greater contrast at the site of accumulation. Gold in conjunction with 
X-ray imaging can be used as a targeting agent to detect small lesions compared to a 
mammogram which has a detection limit of 10 – 20 mm [27]. Detection of small lesions 
and low grade tumors increases the survival rate of patients significantly and makes 
them more responsive to chemotherapy. Another advantage is the increased sensitivity 
and specificity of detection. One of the biggest problems with current diagnostic tools 
such as mammograms is their high false positive rates, which results in several patients 
being overdiagnosed and overtreated. A key reason for this misdiagnosis is the inability 
of a mammogram to distinguish a dense breast or microcalcification from a tumor. The 
use of a targeted contrast agent with computed tomography (CT) or an X-ray source 
eliminates this obstacle and should decrease rates of incorrect diagnosis [28]. CT is 
widely available in all clinics and hospitals, which is significantly cheaper than a biopsy 
or MRI, the second step in screening patients that test positive via a mammogram or the 
first form of screening for other suspected types of cancers. Another key feature using a 
targeted contrast agent such as gold nanoparticles is the broad applicability for detection 
of multiple cancers, such as bladder, ovarian, melanoma, and lung, which do not have 
effective diagnosis modalities that are sensitive as well as widely available [7]. Due to a 
lack of a cost-effective and globally available imaging modality, most patients are 
diagnosed during late stages of tumor development when chemotherapy is less 
effective. 
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Passive versus Active Targeting 
Enhanced Permeation and Retention Effect 
The phenomenon of nanoparticles preferentially accumulating at the tumor was 
identified more than 30 years ago in a poly(styrene-co-maleic acid)-neoCarzinoStatin 
(SMANCS) and albumin conjugate. The preferential accumulation is believed to be due 
to the immature blood vessels as well as an imperfect lymphatic drainage system. The 
combination of two immature systems is the enhanced permeation and retention (EPR) 
effect [29, 30]. 
When tumors reach a size greater than 2-3 mm3 they need to produce new blood 
vessels in order to sustain themselves [31]; however this sprouting of new blood vessels 
is rapid and often irregular leading to a leaky vasculature. The irregularities cause gaps 
in the usually tight endothelial junctions that form the tubular structure of the vessel 
wall, which can range from 200 – 2000 nm. Normal vessels are impermeable to 
particles greater than 2- 4 nm, thus minimizing accumulation within normal, healthy 
tissue. Due to the gaps as well as the shift in pressure between the vessel and the 
remaining tumor, the “enhanced permeation” part of the EPR effect occurs, leading to 
increased, preferential accumulation of drugs and nanoparticles at the site of the tumor 
[29, 32] 
 The second part of EPR is due to the failure of an efficient lymphatic drainage 
system. In normal tissue, extracellular fluid is constantly drained into the surrounding 
lymph nodes at a mean flow velocity of 0.1 – 2 μm sec-1. This drainage is significantly 
slowed down and impaired in the tumor microenvironment, leaving no place for 
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nanoparticles entering the tumor to exit. Particles smaller than 4 nm can be reabsorped 
into the bloodstream; however, most nanoparticles range from 10 – 300 nm [29, 32]. 
 
Active Targeting Molecular Site: Phosphatidylserine 
A key feature of most tumor microenvironments is vascularization, which is necessary 
for overcoming the oxygen diffusion limitation and promoting growth [33]. Tumors 
recruit endothelial progenitor cells and co-opt existing vessels to generate a functional 
reactive stroma and promote angiogenesis [34]. The tumor vasculature is considered 
leaky and highly permeable due to the loss of tight junctions between endothelial cells 
[34]. A marker for the tumor vasculature is phosphatidylserine (PS), which is 
internalized in healthy blood vessels but externalized in tumor microenvironments [7, 
35-37]. PS composes 8 – 15% of the phospholipd layer in mammalian cells [38, 39]. It 
exists to provide structural integrity to the plasma membrane, facilitates binding of 
endofacial surface protein binding, and Ca2+-induced membrane fusion. Exposure of PS 
is considered a hallmark of apoptosis as an “eat me” signal for macrophages to be 
recruited for clearance [38, 40]. 
 Marcophage clearance has three key signals: “find me,” “eat me,” and “engulf 
me” [41, 42]. The “find me” signal is usually a gradient of cytokines and chemokines 
released by apoptotic cells signaling the macrophages to recruit to the site of apoptosis. 
The gradient sets up a migration pattern which directs the phagocyte through the tissue 
and towards the dying cells. The second key signal is the “eat me” signal, which 
includes exposure of PS on the surface. It is estimated that on apoptotic cells, the 
concentration of the PS on the outer leaflet increases by 280-fold within a few hours 
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[41, 43]. Unlike apoptotic cells, which do get recognized, cancer cells also expose 
“don’t eat me” receptors, which prevent recognition and eventual clearance. One of 
most well studied signals is CD47, or integrin-associated protein, which is expressed on 
healthy as well as tumor cells to deter interaction with phagocytes. Other surface 
ligands such as CD31, expressed on the surface of endothelial cells, and CD300a are 
also exposed as potential “don’t eat me signals” [41, 44, 45]. Once recognition has 
occurred, the last signal is “engulf me”. Apototic cells recruit macrophages in order to 
have clearance without the need to elicit an immune response as would be seen in 
necrosis [41]. 
The asymmetry of PS exposure is maintained by three key lipid transporters, 
flippase, floppase, and scramblase [38, 40, 46]. In a healthy cell, flippase transports 
aminophospholipids, PS and phosphatidylethanolamine (PE), from the outer leaflet to 
the inner leaflet of the plasma membrane and is inhibited by calcium [47, 48]. Floppase 
transports cholinephospholipids, phosphatidylcholine (PC) and sphingomyelin (Sph), as 
well as aminophospholipids from the inner leaflet to the outer. A major floppase is the 
ATP-binding cassette (ABC)-transporter ABCC1, which was previously known as the 
multi-drug resistant protein MRP1. ABCC1 acts in multi-drug resistance by increasing 
exocytosis of chemodrugs, thus decreasing the efficacy of the treatment and eventually 
causing resistance [38, 40, 49]. Another key floppase is ABCA1, which promotes 
surface exposure of PS and is present in most mammalian cells. Flippase and floppase 
usually require long periods before sufficient asymmetry of the plasma membrane is 
reached due to their ATP-dependent mechanisms. A third key transporter is scramblase, 
which is a bidirectional transporter that can rapidly flip any phospholipid in any 
11 
direction following influx of Ca2+ and can lead to membrane asymmetry within minutes 
[38, 40, 49]. 
Various physical changes to exposed PS effects its capability to act as an “eat 
me” signal. Studies have compared oxidized versus nonoxidized externalized PS with 
oxidized PS having a higher affinity for macrophage recruitment. Oxidized PS has a 
higher affinity to promote efferocytosis, which is considered a noninflammatory and 
nonimmunogenic process by which clearance occurs [40, 44, 50]. Cells undergoing 
programmed cell death or efferocytosis expose PS as a means to initiate clearance in an 
immunosuppressive manner, or silent clearance [40, 45]. Another key feature is the 
chirality of the PS exposed. A study compared PS in the L and D conformation and 
showed that macrophages engulfed PS isomers in the L but not D confirmation, which 
may also be a difference between PS exposed on apoptotic versus cancer cells [42]. 
Cancer cells along with some viruses and bacteria hijack the PS exposure 
mechanism as a means to generate an immunosuppressive environment [7, 35, 37, 45, 
51]. Viable tumor cells, immature tumor vasculature, and tumor exosomes all expose 
PS as a means to prevent an inflammatory response and heighten immunosuppression 
[45]. 
Studies have shown that different types of cancer cells expose various amounts 
of PS, which may be dependent on the activity of flippase [48]. Tumors with increased 
PS externalization had decreased activity of flippase, which decreases the rate of PS 
transition from the outer to the inner leaflet of the plasma membrane leading to the loss 
of asymmetry [48]. PS externalization is also modulated by the intracellular calcium 
present. Calcium inhibits flippase activity but increases scramblase activity. Tumor cells 
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with increased levels of calcium had more PS exposure, which may be due to the 
decrease in flippase activity but also the increase in scramblase transitioning PS at a 
faster rate towards the outer leaflet [38, 40, 48]. 
 
Active Targeting Molecular Agent: Annexin V 
Active targeting is the use of tumor specific ligands to increase recognition and uptake 
of molecules at the tumor region. Active targeting allows for faster and increased 
accumulation of the molecule at the tumor region. PS can be specifically targeted via 
annexin V (ANXA5) [37, 42]. 
ANXA5 is an anticoagulant protein that belongs to the annexin super-gene 
family. It is a nonglycosylated single chain protein with a C-terminal that contains four 
domains that come together to form the annexin-core. The core has a convex curvature 
that allows it to interact and bind to PS exposed on cancer cells and the tumor 
vasculature [52, 53]. ANXA5 has a Ca2+-dependent binding interaction with PS. The 
Ca2+ binds to the ANXA5 core primarily composed of α-helices, at the C-terminal, 
specifically at the type II Ca2+ binding site [52, 53]. ANXA5 resides as a monomer in 
solution, but forms trimers when interacting with PS, which can lead to internalization 
[54]. A previous study reported a binding dissociation of ANXA5 and PS between 0.1 – 
2 nM [52]. 
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Scope of Thesis 
Most current cancer therapies and imaging tools focus on delivering high doses of the 
drug or contrast agent and relying on the EPR effect for accumulation at the tumor site. 
The high dose is a key limiting factor leading to nonspecific toxicity of the agent. This 
study focuses on the use of the strong interaction between PS, which is exposed on 
tumor cells and vasculature, and ANXA5, a mammalian protein, to deliver targeted 
therapeutic and diagnostic agents to bladder, breast, and ovarian cancer, with the goal of 
eliminating or reducing toxic side effects to normal organs and tissue. This thesis is 
focused primarily on the development of the following for treating or detecting tumors: 
 
1. Photothermal ablation of non-muscle invasive bladder cancer using PS-targeted 
single-walled carbon nanotubes and near-infrared light or radiofrequency. 
a. In vitro and in vivo studies determining the strong, specific binding 
between ANXA5 conjugated single-walled carbon nanotubes and cancer 
cells, as well as photothermal tumor cell death via a 980 nm near-
infrared laser. 
b. Preliminary studies determining the resonance frequency of ANXA5 
conjugated single-walled carbon nanotubes in a radiofrequency field for 
heat-based death of cancer cells. 
2. Enzyme prodrug therapy for the treatment of metastatic ovarian cancer using a 
PS-targeted novel mutant enzyme prodrug (cystathionine gamma-lyase) with 
selenomethionine as the prodrug, in conjunction with immunostimulation. 
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a. In vitro and in vivo studies determining optimum dosage of the enzyme 
prodrug system in conjunction with immunostimulant pairs for a 
synergistic and immune stimulating therapy of metastatic ovarian cancer. 
b. Development of a novel PS-targeting mutant of cystathionine gamma-
lyase and determination of in vitro cytotoxicity compared to a previous 
mutant. 
3. A novel PS-targeted gold nanoparticle for early detection of breast cancer using 
computed tomography (CT). 
 
Chapter II in this dissertation has been submitted to Nanotechnology in July 2017. 
Chapters IV and VI have been written as publications for submission in 2017.  
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Chapter II: Phosphatidylserine Targeted Single-walled Carbon 
Nanotubes for Photothermal Ablation of Bladder Cancer 
Abstract 
Bladder cancer has a 60-70% recurrence rate most likely due to residual tumor left 
behind after a transurethral resection (TUR). Failure to completely resect the cancer can 
lead to recurrence and progression into higher grade tumors with metastatic potential. 
We present here a novel therapy to treat superficial tumors with the potential to 
decrease recurrence. The proposed therapy is a heat-based approach in which bladder 
tumor specific single-walled carbon nanotubes (SWCNTs) are delivered intravesically 
at a very low dose (0.1 mg SWCNT per kg body weight) followed by a short 30 sec 
treatment with a 360° near-infrared (NIR) light that heats only the bound nanotubes. 
Nanotubes are specifically targeted to the tumor via the interaction of annexin V 
(ANXA5) and phosphatidylserine (PS), which is normally internalized on healthy tissue 
but externalized on tumors and tumor vasculature. SWCNTs are conjugated to ANXA5, 
which binds specifically to bladder cancer cells as confirmed in vitro and in vivo. Due to 
this specific localization, NIR light can be used to heat the tumor while conserving the 
healthy bladder wall. In a short-term efficacy study in mice with orthotopic MB49 
murine bladder tumors treated with the SWCNT-ANXA5 conjugate and NIR light, no 
tumors were visible on the bladder wall 24 h after NIR light treatment, and there was no 
damage to the bladder. In a separate survival study in mice with the same type of 
orthotopic tumors, there was a 50% cure rate at 116 days when the study was ended. At 
116 days, no treatment toxicity was observed, and no nanotubes were detected in the 
clearance organs or bladder.  
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Introduction 
Bladder cancer has high costs-per-patient ratios due to the elevated rate of recurrence 
[8, 55, 56]. Approximately 75-85% of patients have Ta/T1 stage non-muscle invasive 
bladder cancer (NMIBC) that can be treated using surgical transurethral resection 
(TUR). TUR is usually followed by intravesical chemotherapy and immunotherapy, 
which has proven to be effective in increasing remission periods; however 70% of 
patients still experience tumor relapse [8, 55-58]. Recurrence is believed to occur due to 
four main mechanisms: incomplete resection, re-implantation, disperse microscopic 
tumors, or new tumor development [8, 55, 57]. A previous study tested the frequency of 
each mechanism and determined incomplete resection and cell re-implantation after 
TUR to be the primary causes of most relapses [55]. Unfortunately, there has been 
limited improvement in therapeutic options for bladder cancer patients over the past 20 
years [58]. Due to this void in research as well as the rapidly increasing costs associated 
with cycles of diagnostics and treatment, we have developed a novel approach to 
thermally ablate tumors using specifically targeted single-walled carbon nanotubes 
(SWCNTs) and near-infrared (NIR) laser light. 
Photothermal ablation is the use of light to heat biologic tissue above 60°C over 
a short time period [59, 60]. Exposure to high temperatures leads to tissue death via 
necrosis and can be used as an alternative for chemoresistive as well as hyperthermic 
resistive tumors [59-61]. A previous study comparing the response of breast cancer to 
hyperthermia, a slow heating of tissue, versus ablation showed that ablation 
temperatures were able to eradicate hyperthermia resistive tumors [60]. 
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A recent study of treating mice with bladder cancer used NIR light in 
combination with anti-epidermal growth factor receptor (anti-EGFR) coated gold 
nanoparticles obtained promising results using a procedure that required surgery to 
expose the bladder [62]. In the current study, we have focused on using targeted single-
walled carbon nanotubes (SWCNTs) and have developed a clinically translatable 
procedure to irradiate the bladder without the need for surgery. 
SWCNTs are gaining more attention as versatile nanoparticles in diagnostics 
and therapeutics for drug delivery, photodynamic therapy, and NIR contrast 
enhancement [63-66]. SWCNTs have an intrinsic excitation in the NIR range (700-1100 
nm) that is released as vibrational energy. This energy is converted into heat that 
induces cell death via coagulative necrosis, rupturing of cell membranes, and denaturing 
of proteins [61, 67, 68]. Biological tissue has an “optimal window” within the NIR 
range making the tissue easily light penetrable up to a few millimeters [61, 64].  
In order to enhance nanotube accumulation within the tumor as well as minimize 
nonspecific heat effects, SWCNTs are conjugated to annexin V (ANXA5), which 
strongly binds with phosphatidylserine (PS) [7, 37, 40, 69]. PS is primarily found in an 
asymmetric conformation on the inner leaflet of the plasma membrane of healthy cells; 
however in the tumor vasculature and cancer cells, it gets externalized, making it a 
specific and versatile targeting receptor for bladder cancer as well as other tumors [7, 
36, 37, 40, 69]. The SWCNT-ANXA5 conjugate is delivered intravesically to the 
bladder for tumor specific accumulation. Intravesical delivery is commonly utilized 
over systemic since it provides a higher payload and the urothelium limits the 
absorption of particles into the bloodstream [56, 64, 68, 70]. 
Due to the strong association of ANXA5 to bladder 
property of nanotubes to absorb NIR light and dissipate energy as heat, this study 
hypothesizes that targeted SWCNT
NIR fiber can be utilized as an alternative to treat NMIBC and reduce relapse rates 
without invasive surgery (fi
specifically target bladder cancer cells 
binding to normal urothelium; combining PS
in a 50% cure rate with no observ
murine bladder tumors, thereby proving the effectiveness and clinical applicability of 
the proposed approach. 
Figure 1. SWCNT-ANXA5 and NIR light combination therapy mechanism.
Cancer targeted SWCNTs are instilled into the bladder via catherization. After a 
clearance period for unbound nanotubes, a globally
light is threaded via a catheter into the 
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Materials and Methods 
Materials 
The plasmid encoding ANXA5, pET-30 Ek/LIC/ANXA5, was previously constructed 
in this lab [64]. Bovine serum albumin (BSA), Alamar Blue reagent, Triton X-100, 
EDTA, and Tris-acetate-EDTA buffer were from Sigma-Aldrich (St Louis, MO). 
Sodium phosphate and sodium dodecyl sulfate (SDS) were from Mallinckrodt 
Chemicals (Phillipsburg, NJ). Paraformaldehyde was from Electron Microscopy 
Sciences (Hatfield, PA). Antifade reagent Fluoro-gel, borate buffer, fluorescein 
isothiocyanate (FITC), poly-L-lysine, and Slide-A-Lyzer dialysis cassettes (3.5 kDa) 
were from Thermo Fisher Scientific (Waltham, MA). The 2 and 100 kDa dialysis 
membranes were from Spectrum Laboratories (Rancho Dominguez, CA). Anti-ANXA5 
(FL-319) was from Santa Cruz Biotechnology (Santa Cruz, CA). Murine bladder cancer 
cells (MB49) and human bladder cancer cells (J82) were from ATCC (Manassas, VA). 
RPMI-1640, Dulbecco’s Modified Eagle, and keratinocyte-SFM cell medium were 
from ATCC (Manassas, VA). Fetal bovine serum (FBS) was from Atlanta Biologicals 
(Lawrenceville, GA). Antibiotics, penicillin and streptomycin, were from Invitrogen 
(Grand Island, NY). (6,5) CoMoCAT SWCNTs (average diameter 0.8 ± 0.1 nm, 
average length 1.5 ± .5 μm ) were provided by Southwest Nanotechnologies, Inc. 
(Norman, OK). The 1,2-distearoyl-sn-glycero-3-phosphoethanolaminepolyethylene 
glycol-maleimide (DSPE-PEG-maleimide; PEG molecular weight of 3.4 kDa) linker 
was from Creative PEGWorks (Winston Salem, NC). 
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 Cell lines and culture conditions 
MB49 cells were transfected with tdTomato (Td) and luciferase (Luc) and J82 cells 
were transfected with Td. Normal bladder cells were HPV immortalized as described 
[71]. MB49-Td-Luc cells were grown in RPMI-1640 medium, and J82-Td cells were 
grown in Dulbecco’s Modified Eagle’s Medium with glucose. Both cell line media were 
enriched with 10% FBS and penicillin/streptomycin antibiotics (100 U ml-1 and 100 µg 
ml-1, respectively). Normal immortalized bladder cells were grown in keratinocyte-SFM 
medium supplemented with 50 µg ml-1 bovine pituitary extract, 5 ng ml-1 epidermal 
growth factor, and penicillin/streptomycin antibiotics (50 U ml-1 and 50 µg ml-1, 
respectively). All cells lines were grown at 37°C with 5% CO2. 
 
 ANXA5 and SWCNT-ANXA5 production 
Recombinant ANXA5 and the SWCNT-ANXA5 conjugate were produced as 
previously described [64]. The conjugation was performed using DSPE-PEG-maleimide 
linker. ANXA5 was characterized via SDS-PAGE, and SWCNT-ANXA5s were 
characterized by UV-Vis-NIR spectroscopy. 
 
 Binding strength 
The dissociation constant for ANXA5 was determined as previously described [64] 
using biotin conjugated ANXA5 on 70% confluent MB49-Td-Luc and J82-Td cells. 
Specific binding was determined by subtracting total binding (medium supplemented 
with calcium) from nonspecific binding (medium supplemented with EDTA). 
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Fluorescent microscopy of SWCNT-ANXA5 in vitro 
MB49-Td-Luc and J82-Td cells were grown to 70% confluence on cover slips. 
SWCNT-ANXA5s were tagged with FITC following a protocol by [64]. SWCNT-
ANXA5-FITCs (20 mg l-1) in 2 mM CaCl2 were incubated with either MB49-Td-Luc or 
J82-Td cells for 2 h followed with PBS washing. The cells were fixed in 4% 
paraformaldehyde. Images were taken on a Nikon fluorescence microscope. 
 
In vitro cytotoxicity studies 
Alamar Blue pre- and post-cell viability assays were conducted to determine the 
cytotoxic effects of NIR and SWCNT-ANXA5s alone and in combination on both 
bladder cancer lines as well as normal bladder cells. Viability assays were conducted on 
cells at 70% confluence followed by either SWCNT-ANXA5 incubation at various 
concentrations for 2 h or NIR treatment for 30 sec at various energy levels. Cells were 
washed, and a second viability assay was conducted 18 h later. 
 
Animal handling procedures 
All procedures complied with a protocol approved by Institutional Animal Care and Use 
Committee (IACUC) of the University of Oklahoma Health Sciences Center. C57BL/6J 
female mice 10 weeks of age, weighing 20 – 22 g were used. Mice were on a standard 
chow diet. All studies on mice were conducted under anesthesia with 2% isoflurane and 
98% oxygen using a nose cone. 
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In vivo laser tolerance 
Fiber insertion and positioning was determined via ultrasound (VEVO 2100) as shown 
in figure 2. The fiber was threaded through a catheter attached to an adapter with a 
resealable end to push the fiber through and a second end with a syringe to fill the 
bladder with air. An in vivo NIR tolerance test at 50 and 100 J cm-2 for 30 sec with a 
globally radiating, 980 nm fiber was conducted. Mice were euthanized 24 h after 
treatment, and H&E staining on bladders was used to determine if damage was caused 
to the urothelium. 
 
 
Figure 2. Ultrasound images of fiber positioning in bladder. 
Ultrasound images of diffusing fiber centered in C57BL-6 mouse bladder in the x-z (a) 
and x-y (b) plane. A centered diffusing fiber ensures one session is required to treat the 
entire bladder and isolated residual tumor cells. 
 
In vivo tumor model 
Mice were anesthetized and catheterized with a 24 gauge catheter through the urethra. 
Urine was expelled and the bladder was washed with PBS. Mouse bladders were 
incubated with 100 μl poly-L-lysine for 20 min to disrupt the glycosaminoglycan 
(GAG) layer and allow for tumor implantation [72]. Bladders were inoculated with 100 
μl of MB49-Td-Luc cells (5 x 105 cells ml-1) for 1 h. All animal studies were conducted 
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once tumor presence was confirmed via bioluminescence on a Carestream X-treme 
Imager. 
 
In vivo SWCNT-ANXA5 specific tumor cell binding 
A mouse with an orthotopic bladder tumor was instilled with 100 μl of SWCNT-
ANXA5s at a concentration of 20 mg l-1 (0.1 mg SWCNTs kg-1) for 90 min. The mouse 
was euthanized 24 h later, and the bladder was collected for H&E and 
immunohistochemistry (IHC). IHC was conducted for SWCNT-ANXA5s using an anti-
ANXA5 to stain the ANXA5 component of the nanotube conjugate. Images were taken 
on a Zeiss light microscope. 
 
Biodistribution 
NIR fluorescence spectroscopy (NS MiniTracer) analysis by Applied NanoFluorescence 
(Houston, TX) was conducted on the bladders of saline and SWCNT-ANXA5s treated 
mice 24 h after instillation. A second spectroscopy was conducted on mice that were 
tumor free 116 days after tumor instillation. Samples for NIR fluorescence spectroscopy 
were prepared as previously described [73]. 
 
In vivo therapy efficacy 
A therapeutic efficacy study combining SWCNT-ANXA5s and NIR light was 
performed. Tumor presence was confirmed with bioluminescence imaging prior to 
study initiation. SWCNT-ANXA5s (100 μl of 0.1 mg kg-1) were instilled for 90 min and 
followed with 30 sec of 50 J cm-2 NIR laser treatment 24 h later. The mice were 
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euthanized 24 h after NIR light treatment, and tdTomato fluorescence was measured 
with a Leica fluorescence dissecting microscope. Fluorescence was quantified via FIJI 
analysis (code for analysis can be found in Appendix C: Laboratory Protocols). A 
second set of mice was monitored every 3-4 days for survival post-treatment. H&E and 




Statistical significance of in vitro studies was assessed using a one-way ANOVA and 
Tukey-Kramer multiple comparisons test with GraphPad Prism software. Statistical 
significance for tumor presence 24 h after treatment was assessed using Pearson’s chi-




In vitro binding and tolerance 
The dissociation constant of ANXA5 binding to MB49-Td-Luc and J82-Td cells was 
4.14 ± 1.30 nM and 0.38 ± 0.20 nM, respectively, confirming a strong affinity of 
ANXA5 for bladder tumors (data can be found in Figure 23 of Appendix A: 
Supplemental Data). Once ANXA5 and PS interaction was confirmed, further 
evaluation of SWCNT-ANXA5s conjugate binding affinity was visualized via 
fluorescence microscopy. As seen in figure 3a, even after the conjugation of SWCNTs 
to ANXA5, ANXA5 still strongly associated with mouse as well as human bladder 
cancer cells. 
Tolerance of bladder cancer as well as normal bladder urothelium cells for 
SWCNT-ANXA5s and NIR light was determined as seen in figure 3b and 3c. SWCNT-
ANXA5 concentrations above 40 mg l-1 were detrimental to normal bladder cells and to 
a lesser extent for MB49 and J82 cells. In order to ensure no damage to healthy bladder 
urothelium occurred due to SWCNT-ANXA5 toxicity, a conservative 20 mg l-1 
concentration of nanotubes was used for all following work. Normal bladder cells had a 
higher tolerance to NIR energies with minimum cytotoxicity seen up to 350 J cm-2. 
Mouse (MB49) and human (J82) bladder cancer cell lines had noticeable decreases in 
viability at 150 J cm-2 and 100 J cm-2, respectively. Combination therapy had a 
significant decrease in cell viability for both cancer cell lines as well (data can be found 







Figure 3. In vitro binding specificity and SWCNT-ANXA5 and NIR tolerance. 
(a) Fluorescence imaging confirming SWCNT-ANXA5 binding to murine (MB49) and 
human (J82) bladder cancer cells. TdTomato transinfected MB49 and J82 cells (left), 
FITC labeled SWCNT-ANXA5s (middle), and composite (right). Scale = 3.2 μm. 
Murine and human bladder cancer lines as well as normal bladder cells were tested to 
determine tolerance to (b) SWCNT-ANXA5s and (c) NIR energy with 30 sec exposure. 
Data is presented as mean ± SE (n = 3). Statistical significance between groups is 
denoted by * (p < 0.01) with control, untreated samples compared against SWCNT-
ANXA5 or NIR treated samples. 
 
In vivo laser tolerance 
Tolerance studies on mice without tumors were conducted to determine the optimal 
energy for NIR radiation which will cause the tumor bound SWCNT-ANXA5s to heat 
without affecting the remainder of the urothelium. Figure 4a depicts H&E results from 
mouse bladders treated with 50 and 100 J cm-2 NIR energy over 30 sec as compared to a 
control bladder. Treatment with 100 J cm-2 resulted in apparent change in the 
urothelium and muscle layer; however 50 J cm-2 led to no change. 
 
In vivo SWCNT-ANXA5 specific tumor cell binding 
In order to benefit from a targeted therapy, nonspecific binding needs to be minimized 
to prevent heating of healthy urothelial tissue. Anti-ANXA5 IHC confirmed that 
SWCNT-ANXA5s were specifically bound to the tumor, and no binding was seen along 
the healthy bladder wall within the same animal (figure 4b). 
Figure 4. In vivo NIR tolerance an
(a) Mice (n = 3) were treated with 0 J cm
sec. Representative histology images show change to the bladder wall and deeper 
muscle layer in mice treated with 100 J cm
had no visible changes 24 h after irradiation. (b) 
was instilled with 100 μl of 20 mg l
bladder collection 24 h later when NIR laser would be applied. Within the same 
bladder, dark brown, positive anti
the tumor while minimum
arrow indicates healthy bladder wall, thick arrow indicates bladder wall with 
* indicates muscle layer. Scale = 10 μm.
 
NIR fluorescence spectroscopy 
25 of Appendix A: Supplemental Data)
0.13% of the injected dose (34.0 ± 10.6% ID/g of bladder) of SWCNT
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Biodistribution 
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bladders of mice with tumors 24 h after SWCNT-ANXA5 instillation. A long-term 
biodistribution study was also conducted on the clearance organs, liver and kidney, as 
well as the bladder of treated mice 116 days after tumor implantation to determine 
clearance. No detectable nanotubes were observed in any of the clearance organs or 
bladder. 
 
In vivo tumor ablation 
Following confirmation of SWCNT-ANXA5s binding to tumor and NIR tolerance, a 
short-term efficacy study was conducted for presence of tumors 24 h post treatment. As 
seen in figure 5a, mice treated with SWCNT-ANXA5s and NIR light combined had no 
detectable tumor fluorescence. A decrease in fluorescence is seen when the bladders are 
given SWCNT-ANXA5s or NIR alone; however all mice still had detectable 
fluorescence, which can eventually lead to tumor re-growth. H&E staining (figure 5b) 
confirmed no visible damage to the bladder of control or treated mice 24 h post-
treatment. 
Recurrence was evaluated by monitoring survival after one cycle of therapy 
compared to saline-treated mice as a control. The median survival was 34 days in the 
control group compared to 76 days in the treated group with 50% of the mice still alive 
at 116 days, when the study was ended (figure 5c). Trichrome staining (figure 5d) was 
conducted on the surviving treated mice to detect any collagen or scar tissue formation 








Figure 5. In vivo therapeutic efficacy study.
(a) MB49 orthotopic tumor
PBS was delivered intravesically for 90 min. After 24 h to allow for 
nanotube clearance, a diffusing 
sec. Bladders were harvested 24 h after therapy to assess 
fluorescence (representative images above graph). Data is presented as mean ± SE (n = 
6). Statistical significance between groups is denoted by * (p < 0.01). (b) H&E staining 
was conducted on bladders 24 h after therapy. No visible signs of damage to th
were detected. (c) Survival of treated and control mice (n = 6) was monitored fo
recurrence of bladder cancer. 
inoculation while half the treated mice were still living at 116 days when the study
terminated. (d) Trichrome staining was conducted on the surviving mice to determine if 
any damage incurred which may cause scar tissue formation and thus disrupt the normal 
mechanical function of a bladder. No scar tissue was observed within the survi
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Bladder cancer has a high rate of recurrence due to incomplete resections as well as 
eventual chemotherapy resistance with no promising alternatives developed over the 
past 20 years [58]. A global heat based approach to recurrent, superficial bladder cancer 
shows promise as a viable therapeutic option to specifically heat the tumor with no 
apparent damage to the healthy urothelium. SWCNTs are conjugated to the protein 
annexin V via a PEG linker, which provides a stealth coating to make them more 
biocompatible and minimize the risk of eliciting an immune response [74]. ANXA5 is a 
mammalian protein which binds specifically and with high affinity only to bladder 
cancer cells, as seen on murine and human bladder cancer cells in vitro as well as on 
orthotopic MB49 tumors in vivo. The strong binding ensures that the heat being 
generated by the nanotubes is contained within the tumor region, thus minimizing 
nonspecific damage to the healthy bladder urothelium. 
In addition to successfully treating bladder tumors, this study has also shown 
that there was no detectable long-term nanotube presence or toxicity from the 
photothermal therapy at 50 J cm-2 based on the following results: (1) the H&E analysis 
showing no visible damage to the bladder 24 h after treatment, and (2) the analysis of 
the mice surviving 116 days post-tumor instillation, which showed no nanotubes in the 
liver, kidney, or bladder as well as no scar tissue formation in the Trichrome stain. The 
50 J/cm2 energy level was used instead of 100 J cm-2 since the higher level was found to 
give some changes to the bladder wall in the study with only NIR light treatment (figure 
4a). It is possible that lower than 50 J cm-2 energy could be used in combination with 
SWCNT treatment. 
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A recent study using a similar photothermal based approach for bladder cancer 
showed promising results with anti-EGFR coated gold nanoparticles; however delivery 
of the NIR light required surgery to expose the bladder, which is not as clinically 
translatable compared to the minimally-invasive intravesical NIR light delivery proven 
effective in this study [62]. A global NIR light also ensures that the entire bladder is 
treated at the same time, thus decreasing the possibility of incomplete treatment which 
is a major cause of recurrence currently. Our approach also requires significantly less 
power (1.7 W cm-2 versus 10 W cm-2 for the gold nanoparticles) which minimizes 
healthy tissue damage for a nonsurgical approach [62]. In contrast to the previous work, 
the proposed therapy also provides a unique adjuvant benefit of blocking PS, which is a 
global immunosuppressive signal in cancer [40]. A recent study tested the effects of 
blocking PS via ANXA5 and saw significant regression of tumor size as well as 
decreases in tumor angiogenesis factors that can be a synergistic addition to the novel 
therapy [36]. 
A preliminary 48 h study was conducted to evaluate the therapeutic efficacy of 
the proposed therapy along with a 24 h post-treatment period to observe any signs of 
therapy induced distress. No visible signs of discomfort or pain were observed. At the 
end of the study, bladders treated with only SWCNT-ANXA5s had some decrease in 
tumor presence, possibly due to the effect of the SWCNT-ANXA5s accumulating in the 
tumor cells in conjunction with the possible adjuvant nature of ANXA5 blockade of 
immunosuppressive PS [36, 40]. There is also a decrease in fluorescence for mice 
treated with only NIR laser, which might be due to the increased susceptibility of 
malignant cells to heat damage because of their reduced ability to efficiently dissipate 
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heat as seen in the in vitro tolerance study [59]. Although there were some decreases in 
tumor fluorescence for only SWCNT-ANXA5 or NIR treated mice, all mice still had 
tumors which will lead to recurrence. On the other hand, all mice treated with SWCNT-
ANXA5s in combination with NIR had no detectable tumor presence 24 h post-therapy. 
Since tumor re-growth is the major problem with the current standard of care 
treatment for NMIBC and results in 70% of patients having tumor relapse, a survival 
study was conducted comparing saline treated control mice and combination treated 
mice [8, 55-58]. The photothermal therapy resulted in a 50% cure rate in the survival 
study, which is higher than treatments used today. This is a remarkable result, given that 
this treatment consists of one 30 sec irradiation versus the usual combination of 
resection, chemotherapy, and immunotherapy for the current standard of care. The cure 
rate should be able to be increased by transitioning to a two- or three-cycle therapy to 
ensure all tumors are treated. No visible change was seen in the bladders treated with 





This study has shown success in the treatment of bladder cancer in mice with a targeted 
photothermal therapy using a very low dose of SWCNTs (0.1 mg SWCNTs kg-1) 
delivered intravesically combined with a 30 sec NIR light treatment at a relatively low 
power density (1.7 W cm-2). This treatment approach is much simpler and less invasive 
than for the current standard of care that normally consists of a combination of 
resection, chemotherapy, and immunotherapy, and in a 116 day survival study with only 
one cycle of therapy a higher cure rate was found compared to what patients now 
experience. It is also significant that no treatment toxicity was observed and no 
nanotubes were detected in the clearance organs or bladders at the end of the survival 
study. In future work, it would be desirable to evaluate the potential of a multi-cycle 
therapy since no signs of treatment toxicity were detected. 
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Chapter III: Targeted Single-Walled Carbon Nanotubes Thermal 
Ablation of Cancer via a Radiofrequency Field 
Abstract 
Single-walled carbon nanotubes (SWCNTs) are promising candidates for tumor ablative 
therapy because of their robust nature and high thermal conductivity. SWCNTs can be 
accumulated preferentially within cancerous tissue via annexin V (ANXA5) surface 
modification that selectively targets phosphatidylserine (PS) externalized on tumor cells 
and tumor vasculature. PS targeting of tumors has previously proven to be effective and 
very specific in vitro as well as in vivo. SWCNT-ANXA5s can be targeted to the tumors 
and mechanically excited via radiofrequency (RF) fields to generate a cell intolerable 
environment. The resonance of SWCNTs in the RF spectrum can be utilized as a 
noninvasive tool to thermally excite tumor targeting nanotubes above ablative 
temperatures (> 47°C). This study focuses on determining the resonance frequency of 





Most late stage tumor treatments focus on palliative therapy rather than a cure. Tumors 
become vascularized when they are as small as 2 - 3 mm3, and are leaky and highly 
permeable due to the loss of tight junctions between endothelial cells [29, 31, 34]. A 
marker for tumor vasculature is phosphatidylserine (PS) which is internalized in healthy 
blood vessels but externalized in tumor vessels and tumor cells [35]. Annexin V 
(ANXA5) is an excellent marker for PS and can be used for targeted tumor therapies [7, 
25, 37, 64, 75] 
Radiofreuency (RF), which can deeply penetrate tissue (> 15 cm) and cause 
minimum damage to normal cells, can be utilized as an effective, noninvasive method 
for cancer treatment. RF based heat generation is dependent on the dielectric properties 
of the material which consists of permittivity, the ability to absorb and dissipate 
electrical energy as heat, and conductivity [76-78]. Raoof et al. compared the 
permittivity of liver and pancreatic tumors against normal tissue and found that the 
permittivity of both tumors was significantly higher than healthy tissue, explaining the 
highly preferential RF heating of the malignant regions [76]. The predisposition of RF 
tumor heating can be enhanced by the use of dielectric nanotubes to avoid damage of 
nonspecific regions such as the liver and spleen [79, 80]. 
In order to dissipate heat into cancerous tissue, nanotubes first need to generate 
thermal energy. Electromagnetic waves physically force nanotubes to vibrate due to the 
dipole formed from the buildup of opposing charges on the ends of the SWCNTs [81-
86]. Heat is carried by acoustic phonons, which are defined as vibrations in the crystal 
lattice, and by electrons. In carbon materials, heat conduction is dominated by phonon 
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transport due to the strong sp2 covalent bonding. There are two types of phonon 
transport regimes: diffusive and ballistic. Thermal transport is diffusive if the size of the 
sample ( ) is much larger than the phonon mean-free path (Λ), which means that the 
phonon undergoes multiple scattering events. Conversely, if   ≪ Λ, then thermal 
transport is ballistic and phonons can propagate without scattering [87]. Nanotube 
thermal conduction transitions from ballistic to diffusive with increasing temperatures 




Figure 6. Schematic of electromagnetic waves inducing carbon nanotube heating. 
When struck with an (1) electromagnetic wave such as RF, (2) nanotubes act like 
dielectrics and physically vibrate. (3) Heat is generated by the vibrations of the crystal 
lattice or phonon transport. (4) As temperature increases phonon transport goes from a 
ballistic to a diffusive regime due to the decreasing mean free phonon path and 
increased scattering. 
 
Nanotubes have a resonant frequency at which the amplitude of vibration is 
significantly higher than at any other frequency within the RF spectrum. Resonance of 
the nanotubes can be predicted using Euler-Bernoulli’s beam theorem; however, it only 
takes into account length and diameter. Furthermore, the beam theory does not consider 
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the additional contributions of surface modifications (ANXA5 and PEGylation), 
number of nanotube shells, or nanotube chirality (metallic or semiconductive) [81-86, 
88]. 
Although SWCNT resonance studies have been conducted, factors such as 
chirality and surface modification have not been taken into consideration. Most studies 
have focused on developing mathematical models to correlate with experimental data 
rather than optimizing SWCNT resonance for applications such as cancer ablative 
therapy [81-86, 89]. Previous studies involving noninvasive RF heating of cancer cells 
have focused on a single frequency (13.56 MHz) with untargeted and targeted gold 
nanoparticles to enhance the tumor ablation effect [76, 79, 90-94]. The novelty of this 
study is to improve tumor ablation by exploring mechanical resonances of SWCNT-
ANXA5s within the RF spectrum that will produce a more effective system; this 
therapy will be further enhanced with an already established, highly specific tumor 
vasculature targeting mechanism. A schematic of the proposed targeted, ablative 




Figure 7. Schematic of tumor vasculature targeted ablative therapy. 
(1) SWCNT-ANXA5s will be delivered systemically and bind preferentially to PS 
exposing tumor vasculature. (2) A RF field will be delivered and tumor bound SWCNT-
ANXA5s will (3) generate heat which will be (4) dissipated into the surrounding 
cancerous tissue and lead to (5) cell death. 
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Materials and Methods 
Materials 
The plasmid encoding ANXA5, pET-30 Ek/LIC/ANXA5, was previously constructed 
in this lab [64].Bovine serum albumin (BSA), Alamar Blue reagent, Triton X-100, 
EDTA, and Tris-acetate-EDTA buffer were from Sigma-Aldrich (St Louis, MO). 
Sodium phosphate and sodium dodecyl sulfate (SDS) were from Mallinckrodt 
Chemicals (Phillipsburg, NJ). The 2 and 100 kDa dialysis membranes were from 
Spectrum Laboratories (Rancho Dominguez, CA). (6,5) CoMoCAT SWCNTs (average 
diameter 0.8 ± 0.1 nm, average length 1.5 ± .5 μm ) were provided by Southwest 
Nanotechnologies, Inc. (Norman,OK). The 1,2-distearoyl-sn-glycero-3-
phosphoethanolaminepolyethylene glycol-maleimide (DSPE-PEG-maleimide; PEG 
molecular weight of 3.4 kDa) linker was from Creative PEGWorks (Winston Salem, 
NC). 
 
ANXA5 and SWCNT-ANXA5 production 
Recombinant ANXA5 and the SWCNT-ANXA5 conjugate were produced as 
previously described [64]; the conjugation was performed using a DSPE-PEG-
maleimide linker. ANXA5 was characterized via SDS-PAGE, and SWCNT-ANXA5s 
were characterized by UV-Vis-NIR spectroscopy. 
 
Resonant Frequency Determination 
Samples of SWCNT-ANXA5s (75 mg l-1) were placed in glass vials and mounted in a 
five turn coil connected to a RF generator. SWCNT-ANXA5s rate of heating was 
42 
determined with a forward looking infrared (FLIR) thermal imager by measuring the 
temperature change every 30 sec. A buffer control was run at 45 MHz, which produced 
the highest SWCNT-ANXA5 heating rate, to confirm negligible buffer heating. The 





In order to assess the validity of an improved thermal ablation therapy due to SWCNT-
ANXA5 resonance within the RF spectrum, preliminary studies by J.P.P’s & 




Figure 8. Resonance frequency analysis. 
Preliminary analysis conducted by J.P.P’s & Consulting, Inc. at a concentration of 75 
mg l-1 SWCNT-ANXA5 and a volume of 1 ml. Change in temperature was determined 
with a FLIR thermal imager. 
 
A similar study was conducted within our lab to determine the SWCNT-ANXA5 (75 
mg l-1) rate of heating by a 980 nm near-infrared (NIR) laser, which has been effective 
in causing in vivo tumor eradication for breast and bladder cancer. The rate of heating 
was determined to be 0.603°C sec-1 (Ti = 25.3°C and Tf = 43.39°C) at a power of 3.67 
W cm-2 for 30 sec which is lower than the 45 MHz (1.088°C sec-1) but higher than the 
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13.56 MHz (0.095°C sec-1) rate, which has previously been reported to cause SWCNT 
based thermal ablation [95]. 
Discussion 
As mentioned previously, SWCNTs have a mechanical resonance within the 
radiofrequency range that can be exploited to improve their rate of heating. It is 
expected that at the resonance frequency, the rate of heating will be at its maximum [17, 
86, 96, 97]. Euler-Bernoulli’s beam model is a simplified theory of elasticity which can 
be used estimate the resonance frequency of a SWCNT based on length and diameter 













Equation 1. Euler-Bernoulli's beam model for mechanical resonance frequency. 
   is the resonance frequency,    is 4.73 for the first harmonic [83, 85],   is the length, 
   and    are the outer and inner diameters respectively,   is the Young’s modulus 
which is 1 TPa [83, 85], and   is the density which is 0.094 g cm-3 (SWeNT, Inc.). 
 
By solving the preceding equation with the known parameters,    = 42    ; however 
this does not take into account the ANXA5 molecules on the surface, the chirality, and 
any defects in the SWCNTs. As seen in the results above, even though the expected 
resonance is around 42 MHz, no peak is seen up to 45 MHz. In order to determine the 
true resonance, further experimental tests will need to be conducted. 
 A previous study combining SWCNTs with 13.56 MHz RF was conducted with 
promising results [95]. The SWCNTs were directly injected into the hepatic xenograft 
tumors of rabbits followed by 800W of RF for 2 minutes. Complete tumor necrosis was 
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reported 48 h post-therapy compared to the mice treated only with RF. Compared to the 
previous study, our approach is further advantageous by 1) using targeted nanotubes 
which specifically bind to tumors over healthy tissue, 2) eliminating the need for 
intratumoral injections, and 3) the resonance frequency of the nanotubes will be used to 
deliver more heat in a short period leading to complete primary and secondary tumor 
death. 
The overall objective of targeting the nanotubes via the ANXA5-PS interaction 
is to localize a highly concentrated SWCNT-ANXA5 solution within the tumor as 
compared to the other organs. When a RF field is applied, tumor sites will be treated 
because of a higher rate of heating compared to the surrounding organs. Previous 
literature has shown that SWCNT concentration and rate of heating have a linear 
relationship and that there is preferential heating of tumor sites with just RF fields, 
which can be enhanced by localized nanoparticles [79, 95]. A previous study confirmed 
the lack of acute or chronic damage because of RF heating of healthy tissue with 
nonspecific nanoparticle accumulation [79].  
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Conclusions 
The work conducted in this study will be a stepping stone for an ablative therapy that 
can be translated relatively easily for clinical treatment of tumors. In order to evaluate 
the full potential of this regime, further testing into a wider RF range will need to be 
assessed to determine the optimal peak while still maintaining whole body penetration 
for a noninvasive treatment alternative. A network analyzer is being developed to test a 
wider range of RF frequencies to determine resonance (schematic of network analyzer 
can be found in Figure 26 of Appendix A: Supplemental Data). Further testing of 
biodistribution will need to be conducted to evaluate any cytotoxic effects due to acute 
SWCNT-ANXA5 accumulation. Blood clearance will also need to be assessed in order 
to ensure that the RF field will not affect normal tissue. Combining SWCNT-ANXA5 




Chapter IV: Enzyme Prodrug System in Combination with 
Immunostimulation for Treatment of Metastatic Ovarian Cancer 
Abstract 
Approximately 75% of ovarian cancer is diagnosed once metastasis to the peritoneal 
cavity has occurred, which results in a 70% mortality rate. The current treatment option 
includes a combination of a cytoreductive surgery with platinum-based chemotherapy 
given intraperitoneally or intravenously. A large proportion of patients quickly develop 
platinum-resistive tumors, which are considered terminal. In order to provide an 
alternative for resistive tumors as well as decrease mortality rates, a novel fusion 
protein, mCTH-ANXA5, has been developed for the treatment of high grade, metastatic 
ovarian cancer. The fusion protein combines annexin V (ANXA5), an ovarian tumor 
and tumor vasculature targeting protein, with a mutated cystathionine gamma-lyase 
(mCTH), an enzyme converting selenomethionine (SeMet) into toxic methylselenol. 
The fusion protein is targeted to the tumor followed by addition of a nontoxic prodrug, 
SeMet, which is locally converted into a cytotoxic reactive oxygen species (ROS) 
generating drug, methylselenol. Excess ROS causes oxidative stress leading to DNA, 
membrane, and mitochondrial damage and eventual tumor cell death. In order to further 
enhance the therapeutic efficacy of this system, anti-CD73 and anti-OX40 
immunostimulants were combined to produce a significant increase in survival from 45 
days for untreated to 57 days for treated mice, and a decrease in tumor burden in mice 
with orthotopic metastatic ovarian tumors. Further evaluation of the combination 
therapy revealed a strong antibody-mediated immune response, and an increase in 
infiltration of cytotoxic T-cells along with a decrease in tumor promoting immune cells 
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such as myeloid-derived suppressor cells and regulatory T-cells. This study 
demonstrates the efficacy of a synergized, multi-drug system by attacking the tumor as 




Ovarian cancer has a 70% mortality rate largely due to 75% of diagnoses occurring after 
metastases to the peritoneal cavity [98]. The current standard of care is a cytoreductive 
surgery followed by platinum-based chemotherapy delivered intraperitoneally, which 
increases tumor free survival by only 5-months. Novel therapies for metastatic ovarian 
cancers need to be developed, which will increase tumor free survival as well as avoid 
aggressive surgery that increases the chances of complications [98]. A novel enzyme 
prodrug system is proposed in combination with immunostimulation for the treatment 
of aggressive, metastatic ovarian cancer. 
  An enzyme prodrug approach is a two-step therapy that involves the delivery of 
a drug activating enzyme to the tumor followed by a nontoxic prodrug that is converted 
into a highly toxic drug by the enzyme [22, 23]. To be considered a successful enzyme 
prodrug therapy, a few key requirements need to be met: 1) the enzyme should be 
nonhuman or absent/minimally expressed in normal tissue, 2) the enzyme must remain 
highly active once at the tumor, 3) the prodrug must be activated by the tumor specific 
enzyme but not by endogenous enzymes in the remainder of the body, 4) the prodrug 
and activated drug must be highly permeably to allow for a bystander effect, 5) the half-
life of the drug must be optimal to allow for diffusion into the surrounding cancer cells 
but limit systemic leakage, and 6) there must be a high therapeutic index between the 
prodrug and the drug [22, 23]. We have developed a novel enzyme prodrug system 
combining a fusion protein composed of the targeting protein annexin V (ANXA5) with 
mutated cystathionine gamma-lyase (mCTH) enzyme and selenomethionine, a nontoxic 
prodrug. 
50 
The fusion protein is composed of ANXA5, which specifically and strongly 
binds to phosphatidylserine (PS) that is exposed on tumor cells and tumor vasculature 
[7, 25, 26, 37]. PS is normally internalized on healthy cells, thus reducing the chances 
of nonspecific accumulation and eventual toxicity of the fusion protein. The second part 
of the fusion protein is composed of mCTH, an enzyme that generates a local cytotoxic 
agent against tumor cells. Cystathionine gamma-lyase (CTH) is a mammalian enzyme 
that breaks down cystathionine into cysteine, α-ketobutyrate, and ammonia [25]. Wild 
type CGL has no activity towards selenomethionine; however three point mutations to 
the enzyme (mCTH) allows it to develop catalytic activity to the prodrug, 
selenomethionine (SeMet), and generate a highly toxic drug, methylselenol, which 
generates reaction oxygen species (ROS) [99]. Increased ROS accumulation induces 
oxidative stress and leads to membrane, mitochondrial, and DNA damage with eventual 
cell death [25, 100, 101]. 
The mutant CTH (mCTH) also has activity towards conversion of methionine 
into methanethiol, α-ketobutyrate, and ammonia, which has been proposed to aid in the 
regression of multiple tumors including human ovarian cancers [102]. Methionine is a 
key amino acid that is used in protein synthesis as well as the de novo pathway or 
methylation cycle in cell function [102, 103]. Through the de novo pathway, methionine 
gets converted into homocysteine. Homocysteine is then converted into glutathione, 
which reduces ROS, through the trans-sulfuration pathway [102, 103]. In normal cells, 
homocysteine is methylated back into methionine making the cells methionine-
independent; however, cancer cells either lack or have mutated forms of methionine 
synthase which methylates homocysteine, thus blocking their source of a key amino 
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acid, methionine, and making them methionine-dependent [102, 103]. mCTH-ANXA5 
in conjugation with the prodrug SeMet can provide a dual mechanism for human 
ovarian cancer death by: 1) converting nontoxic SeMet into a ROS generating toxic 
drug and 2) depriving cells of methionine that in turn limits the amount of glutathione 
produced, which actively reduces ROS to protect the cell from oxidative stress [102, 
103]. 
 In conjunction with the enzyme prodrug system, immunostimulant combinations 
of anti-PD-1, anti-CD73, and anti-OX40 are studied to determine the most synergistic 
immune system activators. PD-1 ligands are present on tumor cells as inhibitory surface 
markers that interact with PD-1 receptors on T-cells to render them anergic, exhausted, 
or dead, thus preventing a T-cell mediated immune response and tumor cell clearance 
[104-108]. Upregulation of PD-1 expression has been associated with higher grade 
ovarian tumors with poor prognosis and a high risk of recurrence [104-107]. Anti-PD-1 
blockade of the PD-1 receptors present on T-cells may prevent the interaction of tumor 
PD-1 ligands with immune cells and minimize immune suppression. 
Another key immune modulator, CD73, participates in the conversion of 
adenosine monophosphate (AMP) into adenosine, which is an immunosuppressive 
molecule. Adenosine interacts with A2A receptors on regulatory and effector T-cells 
[108-110]. On regulatory T-cells, A2A receptor activation by adenosine triggers a 
positive feedback loop to promote regulatory T-cell expansion and immunsuppressive 
chemokine production, which in turn promotes more cell expansion. On the other hand, 
A2A receptor activation on effector T-cells inhibits immune promoting cytokines and 
cell proliferation. CD73 has also been shown to be specifically upregulated in human 
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ovarian cancer cells, and there is a strong correlation between increased expression of 
CD73 and severity of tumor grade [108, 110, 111]. Due to this upregulation, anti-CD73 
antibodies are proposed as a combinatorial approach with the enzyme prodrug system to 
decrease adenosine production and promote proliferation of effector T-cells and 
downregulation of regulatory T-cells. 
Since anti-PD-1 and anti-CD73 blockade work to promote effector T-cell 
recruitment and activation, anti-OX40 was evaluated due to its co-stimulatory function 
on effector T-cell activation and regulatory T-cell augmentation [107, 112, 113]. OX40 
is expressed by effector T-cells following T-cell receptor recognition by antigen 
presenting cells to stimulate activation. In order to promote activation of tumor 
recognizing effector T-cells, anti-OX40 is administered to act as a co-stimulatory signal 
to promote tumor regression. 
 Due to the increasing evidence of a strong correlation between increased CD73 
presence and high grade, metastatic ovarian cancer as well as the co-stimulatory 
activation mechanism of anti-OX40, it is hypothesized that combining anti-CD73 and 
anti-OX40 with a targeted ROS generating therapy will result in a decrease in 
metastatic ovarian cancer. Figure 9 depicts a schematic of the multi-pronged approach 
proposed. This study demonstrates that mCTH-ANXA5 with SeMet alone can cause a 
decrease in tumor burden; however the addition of anti-CD73 and anti-OX40 
significantly decreased overall tumor weight and increased survival of mice against 
untreated, saline control as well as mice treated with only the enzyme prodrug system. 
The addition of anti-CD73 and anti-OX40 also caused an increase in cell-mediated 
immunity by increasing the tumor infiltrating ratio of cytotoxic T-cells to tumor 
suppressing immune cells
immunity when combining an
versus either antibody alone or the control, untreated mice. The overall increase in 
survival, decrease in tumor burden, and increase in immune response sheds promise on 
the use of a combinatorial approach of
OX40 as an alternative therapy for high grade, metastatic ovarian cancer.
 
Figure 9. Schematic of the proposed therapy.
This therapy combines an ROS generating enzyme 
ANXA5/SeMet with immunostimulatants, anti
approach to metastatic ovarian cancer. The enzyme prodrug system involves delivery of 
a fusion protein with ANXA5 on one end to bind specifically to phosphatidylserine 
expressing tumor cells and tumor vasculature, and mutated cys
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. There is also a significant increase in antibody
ti-CD73 and anti-OX40 with mCTH-ANXA5 and SeMet 
 mCTH-ANXA5, SeMet, anti-CD73, and anti
 
prodrug system mCTH









(mCTH) on the other end. Following unbound mCTH-ANXA5 clearance, a nontoxic 
prodrug, selenomethionine (SeMet), is delivered and converted locally by the fusion 
protein into a toxic drug, methlyselenol, which generates reactive oxygen species 
(ROS). ROS causes tumor cell death by damaging the cell membrane, mitochondria, or 
DNA as seen in the left panel. Mice are treated with the enzyme prodrug system to 
induce tumor regression and increase overall survival. Immunostimulants, anti-OX40 
(αOX40) and anti-CD73 (αCD73), are delivered to activate an immune response 
towards the tumor. Anti-OX40 (middle panel) binds to OX40 present on T-cells as a co-
stimulatory molecule to keep them activated and cause expansion once they are primed 
by antigen presenting cells to attack the tumor. Anti-CD73 (right panel) binds to CD73 
receptors on tumor cells, which converts adenosine monophosphate (AMP) into 
adenosine. Adenosine interacts with A2A receptors on effector and regulatory immune 
cells to decrease proliferation of tumor suppressing immune cells and increase 
expansion of tumor promoting immune cells.  
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Materials and Methods 
Materials 
The plasmid encoding mCTH-ANXA5, pET-30 Ek/LIC-mCTH-ANXA5, was 
previously constructed in this lab [25]. Bovine serum albumin (BSA), Alamar Blue 
reagent, Triton X-100, EDTA, selenomethionine, and Tris-acetate-EDTA buffer were 
from Sigma-Aldrich (St Louis, MO). Sodium phosphate and sodium dodecyl sulfate 
(SDS) were from Mallinckrodt Chemicals (Phillipsburg, NJ). Paraformaldehyde was 
from Electron Microscopy Sciences (Hatfield, PA). Antifade reagent Fluoro-gel, borate 
buffer, streptavidin coated ELISA plates, Alexa-488, Deep Red Plasma Membrane 
stain, DAPI, flow cytometry staining buffer, fixation/permeabilization buffer, 
permeabilization buffer, and Slide-A-Lyzer dialysis cassettes (3.5 kDa) were from 
Thermo Fisher Scientific (Waltham, MA). The 2 and 100 kDa dialysis membranes were 
from Spectrum Laboratories (Rancho Dominguez, CA). Dulbecco’s Modified Eagle cell 
medium was from ATCC (Manassas, VA). Fetal bovine serum (FBS) was from Atlanta 
Biologicals (Lawrenceville, GA). Antibiotics, penicillin and streptomycin, were from 
Invitrogen (Grand Island, NY). All antibodies were from BioLegends (San Diego, CA). 
All immunostimulants were from BioXcell (West Lebanon, NH). 
 
Cell lines and culture conditions 
ID8 p53-/- cells were a gift from Dr. McNeish. The cell line was grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with glucose and was enriched with 4% fetal 
bovine serum (FBS), 1X insulin transferrin selenium (ITX-100), and 
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penicillin/streptomycin antibiotics (100 U ml-1 and 100 µg ml-1, respectively). Cells 
were grown at 37°C with 5% CO2. 
 
 mCTH-ANXA5 production 
Recombinant mCTH-ANXA5 was produced and analyzed via SDS-PAGE and a 
methionine activity assay was conducted as previously described [25]. 
 
Binding strength 
The dissociation constant for mCTH-ANXA5 was determined as previously described 
[25]  using biotin conjugated mCTH-ANXA5 on 70% confluent ID8 p53-/- cells. 
Specific binding was determined by subtracting total binding (medium supplemented 
with calcium) from nonspecific binding (medium supplemented with EDTA). 
 
Fluorescent microscopy of SWCNT-ANXA5in vitro 
ID8 p53-/- cells were grown to 70% confluence on cover slips. mCTH-ANXA5 was 
tagged with Alexa-488 following the company’s protocol. mCTH-ANXA5-Alexa-488 
(100 nM) in 2 mM CaCl2 was incubated with ID8 p53
-/- cells for 2 h followed with PBS 
washing. Cells were fixed in 4% paraformaldehyde, and the nucleus and plasma 
membrane were stained with DAPI and Deep Red Plasma Membrane stain, 
respectively. Images were taken on a Nikon fluorescence microscope. 
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In vitro cytotoxicity studies 
Alamar Blue cell viability assays were conducted to determine the cytotoxic effects of 
mCTH-ANXA5 combined with SeMet on ID8 p53-/- cells over 3 days in 24-well plates 
as previously described [25]. 
 
Mouse tumor models and treatments 
All procedures complied with a protocol approved by Institutional Animal Care and Use 
Committee (IACUC) of the University of Oklahoma Health Sciences Center. C57BL/6J 
female mice 6 weeks of age, weighing 18 – 20 g were used. Mice were on a standard 
chow diet. Mice were injected with 5 x 106 ID8 p53-/- cells by intraperitoneal (i.p.) 
injection. Mouse body weight was monitored every 3-4 days. Mice bearing ID8 p53-/- 
tumors were randomized into groups (6 to 9 per group) prior to initiation of treatment 2 
weeks after inoculation. mCTH-ANXA5 fusion protein (10 mg/kg) was administered 
over 21 days either daily, every 3 days, or every 7 days by i.p. injection. SeMet (5 
mg/kg i.p.) was administered 10 h post-fusion protein. Immunostimulants, anti-OX40 
(10 mg/kg i.p.), anti-CD73 (5 mg /kg i.p.), and anti-PD-1 (5 mg/kg i.p.), were 
administered on days 10, 14, and 18 post-tumor inoculation as seen in figure 10. Mice 
were euthanized once ascites development occurred or animals seemed distressed, and 
tumor, blood, and organs were collected. 
Figure 10. Study progression timeline.
C57BL/6J mice are inoculated with 5 x 10
for 10 - 14 days. Combinations of anti
PD-1 (αPD-1) are given i.p. 10, 14, and 18 days post
prodrug system, mCTH
every 3 days, or once a week. The fusion protein, mCTH
SeMet, are given 10 h apart.
 
Mice with orthotopic ovarian tumors were treated for 1 week with the complete 
combination therapy, mCTH
mice were euthanized 24 h
for H&E. Images were taken on a Zei
 
Mice were euthanized 21 days post
collected for flow cytometry analysis
Laboratory Protocols). Lymph nodes were kept in
Lymph nodes were mechanically dissociated with tweezers and strained through a 70 
μm filter with 3 ml of flow cytometr
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6 ID8 p53-/- cells i.p., and tumors are grown 
-CD73 (αCD73), anti-OX40 (αOX40)
-tumor inoculation. The enzyme 
-ANXA5 with SeMet, is given over a 21 day period either daily, 
-ANXA5, and the prodrug, 
 
In vivo mCTH-ANXA5 toxicity 
-ANXA5 with SeMet, anti-CD73, and anti
 later, and the liver, lungs, kidney, and heart 
ss light microscope. 
Flow Cytomerty Analysis 
-inoculation, and the mesenteric lymph nodes
 (more details can be found in Appendix C: 
 DMEM media on ice until use. 







1000 g for 5 min and the supernatant was discarded. Another 3 ml of flow cytometry 
buffer was added to resuspend and recentrifuge the cells. Cells were counted and 
resuspended in flow cytometry buffer to a final concentration of 10 x 106 cells ml-1. 
Cells (100 μl) were stained (stain 1) for myeloid-derived spleen cells (MDSCs), 
macrophages, CD8+ T-cells, and regulatory T-cells separately with 50 μl antibody 
mixture for 1 h at 4°C, protected from light. Antibody cocktails for each cell stain are 
listed in table 1, and flow cytometry staining buffer was used to bring the final volume 
to 50 μl. Cells were washed three times with 1 ml of flow cytometry staining buffer 
followed by 5 min of centrifuging at 1000 g; the supernatant was discarded each time 
and cells were resuspended in 1 ml of fresh flow cytometry staining buffer. After the 
last wash, cells were suspended in 1 ml of fixation/permeabilization working solution 
for 1 h at 4°C, protected from light. Cells were washed three times with 1 ml of 
permeabilization buffer followed by 5 min of centrifuging at 1000 g; the supernatant 
was discarded each time and cells were resuspended in 1 ml of fresh permeabilization 
buffer. After the last wash, cells were suspended in 100 μl of permeabilization buffer 
with 2 μl of 2% bovine serum albumin (BSA) for 15 min at 25°C, protected from light. 
Without washing, either 2.5 μl PE-FoxP3 or permeabilization buffer (stain 2) was added 
to the cells for 30 min at 25°C, protected from light. Cells were washed three times with 
1 ml permeabilization buffer followed by 5 min of centrifuging at 1000 g; the 
supernatant was discarded each time, and cells were resuspended in 1 ml of fresh 
permeabilization buffer. After the last wash, cells were suspended in 500 μl of flow 





Table 1. Antibodies for flow cytometry analysis. 
Flow cytometry staining for immune cells from the mesenteric lymph nodes of 
C57BL/6J mice were analyzed to evaluate the effect of immunostimulantion. 
 
Antibody Titers 
ID8 p53-/- cell specific antibody titers were determined based on modified protocols 
from [114, 115]. ID8 p53-/- cells were grown to 70% confluence on a 96-well plate. 
Blood samples were collected from mice on day 21 post-inoculation. A sandwich 
ELISA assay was performed by incubating cells with various plasma dilutions at 37°C 
for 2 h. Plates were washed with media and incubated with HRP conjugated goat anti-
mouse IgG and IgM (1:5000 dilution). Excess IgG and IgM were washed with media 
and a colormetric analysis was conducted with o-phenylenediamine (OPD) for 
quantification on a BioTek Synergy plate reader. A standard curve with different 
concentrations of HRP conjugated goat anti-mouse IgG and IgM was generated (more 




Statistical significance of in vitro cell survival and in vivo tumor weight and immune 
response studies was assessed using a one-way ANOVA and Tukey-Kramer multiple 
comparisons test with GraphPad Prism software. Statistical significance for survival 
was assessed using the log-rank (Mantel-Cox) test with a 0.05 significance level. 
 
  
The dissociation constant of mCTH
nM, confirming a strong affinity of mCTH
be found in Figure 27 of Appendix A: Supplemental Data)
(figure 11a) was used to v
and ovarian cancer cells 
has a strong binding affinity for endothelial cells representative of PS exposure of the 
tumor vasculature [25]. 
 In addition to binding, the cytotoxic efficacy of a ROS damage based system 
was proven effective in vitro
cell death is seen after only one dose of mCTH
with increasing cytotoxicity at




In vitro binding and cytotoxicity 
-ANXA5 binding to ID8 p53-/- cells was 18.5 ± 6.1 
-ANXA5 for ovarian cancer cells
. Fluorescence microscopy 
isualize the interaction of Alexa-488 tagged mCTH
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Figure 11. In vitro binding specificity and cytotoxicity of the enzyme prodrug 
system. 
(a) Fluorescence imaging confirming mCTH-ANXA5 binding to ovarian cancer cells. 
Deep red stained plasma membrane (red), Alexa-488 labeled mCTH-ANXA5 (green), 
and DAPI stained cell nucleus (blue). Scale = 15 μm. (b) Cytotoxicity of murine (ID8 
p53-/-) ovarian cancer cells to increasing concentrations of SeMet in the presence of 
mCTH-ANXA5 was determined. Data is presented as mean ± SE (n = 3). Statistical 
significance between groups is denoted by *** (p < 0.001) with control, untreated cells 
compared against enzyme prodrug treated cells. 
 
In vivo fusion protein dosage study 
A dosage study was conducted by delivering the enzyme prodrug system every day, 
every 3 days, or once a week to determine the most effective cycle of treatment that 
would induce greatest tumor regression with the lowest drug dose. As seen in figure 
12a, delivering the enzyme prodrug system every day or every 3 days gave tumor 
regression; however, a continuous delivery of the enzyme prodrug system every day 
yielded the greatest decrease in final tumor load 2 weeks after the end of the study.
 
In vivo immunostimulant combination study
Combinations of anti-PD
the enzyme prodrug system to evaluate the synergis
multi-pronged therapy approach. Figure 12
after therapy ended with three doses of the respective immunostimulant combinations 
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Figure 12. Enzyme prodrug system dosage and immunostimulant study. 
Treatment started 2 weeks after inoculation with 5 x 106 ID8 p53-/- cancer cells. Tumor 
weight 2 weeks post-therapy is shown. (a) Mice were treated with mCTH-ANXA5 and 
SeMet daily, every 3 days, or every 7 days to optimize dosage. (b) A pilot study 
comparing the synergistic effect of different combinations of immunostimulants with 
the enzyme prodrug system administrated daily. Immunostimulants, anti-PD-1 (αPD-1), 
anti-CD73 (αCD73), and anti-OX40 (αOX40), were administrated on days 10, 14, and 
18 post-tumor inoculation. Data are presented as mean tumor weight ± SEM (n = 6). 
Statistical significance of saline treated versus combination treated mice is indicated by 
* (p < 0.05) and ** (p < 0.01). 
 
Long-term survival study 
Tumor survival was monitored to evaluate the long-term efficacy of the proposed 
therapy. As seen in figure 13a, mice treated with the enzyme prodrug system in 
combination with anti-CD73 and anti-OX40 had a significant increase in survival 
compared to the control, saline treated mice. The median survival went from 45 – 47.5 
days for saline and control treated mice to 57 days for mCTH-ANXA5/SeMet with both 
immunostimulants treated mice (Table 2). H&E analysis of the liver, lungs, kidney, and 
heart showed no noticeable change in tissue morphology between healthy non-tumor 
bearing mice and saline or combination treated mice (figure 13b). 
 
Figure 13. Survival and toxicity of enzyme prodrug synergistic therapy.
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Table 2. Median survival statistics. 
Kaplan-Meier survival curves for all groups of mice (n = 6 – 7) with ID8 p53-/- tumors 
were analyzed for significance against saline and the full combination treated mice. 
Log-rank determined p-values are presented and significance is indicated * (p < 0.05) 
and ** (p < 0.01). 
 
 Further evaluation of cell- and antibody-mediated immunity was compared via 
flow cytometry of the mesenteric lymph nodes and antibody titers towards ID8 p53-/- 
cancer cells, respectively. The addition of anti-CD73 as well as the enzyme prodrug 
system caused an increase in CD8+ cytotoxic T-cells in the lymph nodes of mice 
inoculated with metastatic ovarian cancer (figure 14b). There was a significant decrease 
in regulatory T-cells in mice treated with anti-OX40 compared to untreated, saline mice 
(figure 14c), as well as with anti-OX40 or anti-OX40 and anti-CD73 combined with the 
enzyme prodrug system mice. The addition of immunostimulation with the enzyme 
produg system caused an overall increase the ratio of cytotoxic T-cells to suppressive 
MDSCs (figure 14d) and regulatory T-cells (figure 14e). Combining anti-CD73 with 
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anti-OX40 also caused an increase in tumor infiltrating macrophages as seen in figure 
14f. 
 In addition to a cell-mediated immune response, a stronger antibody-mediated 
immune response is detected against ID8 p53 -/- ovarian cancer cells as seen in figure 
14g. There is no difference in antibody presence within the plasma of healthy mice 
without tumors and saline treated ovarian cancer mice; however with the addition of 
anti-CD73 or anti-OX40 with and without the enzyme prodrug system, a slight increase 
in antibody presence specifically to ovarian cancer cells is detected. The greatest 
increase in antibodies is seen with the combination of anti-CD73 with anti-OX40 with 










Figure 14. Cell- and antibody-mediated immune response generated due to the 
addition of immunostimulants. 
(a) Flow cytometry schematic for identification of myeloid-derived suppressor cells 
(MDSCs) that are neutrophils (CD11b+ Ly-6G+) or monocytes (CD11b+ Ly-6C+), 
macrophages (CD11b+ F4-80+), cytotoxic T-cells (CD8+ CD3e+), and regulatory T-
cells (CD25+ CD4+ FoxP3+) in the mesenteric lymph nodes of C57BL/6J mice with 
orthotopic metastatic ovarian tumors (ID8 p53-/-). The mesenteric lymph nodes were 
collected 21 days post-inoculation of tumor cells for flow cytometry analysis. (b) 
Percent of single lymphocytes that are cytotoxic T-cells (CD3e+ CD8+). (c) Percent of 
single lymphocytes that are regulatory T-cells (CD4+, FoxP3+, and CD25+). (d) Total 
MDSCs were identified as sum of single lymphocytes that were either neutrophilic 
(CD11b+ Ly-6G+) or monolytic (CD11b+ Ly-6C+). The percent of total MDSCs was 
compared against the percent of cytotoxic T-cells as previously identified. (e) The 
percent of total regulatory T-cells was compared against the percent of cytotoxic T-
cells. (f) Percent of single lymphocytes that are macrophages (CD11b+ F4-80+). (g) 
Antibody titers against ID8 p53-/- cells in the plasma of mice 3 days after 
immunostimulatants were given (day 21 post-inoculation). Data is presented as mean ± 
SEM (n = 3). Statistical significance of saline treatment versus combination treatment is 





Ovarian cancer is usually detected once metastasis to the peritoneal cavity has occurred. 
Current standard of care involves a cytoreductive surgery in combination with 
platinum-based chemotherapy, which has only a 5-month increase in survival due to 
development of resistance. A novel approach for metastatic ovarian cancer that can treat 
multiple nodules throughout the peritoneal cavity with minimum damage to healthy 
tissue has been developed combining an enzyme prodrug system with 
immunostimulation. 
Human bodies work to generate and eliminate ROS in a homeostatic 
environment; however, tipping the scale towards a higher ratio of generation versus 
elimination of ROS can lead to cell death [102, 103]. In this therapy, the enzyme 
prodrug system works to generate a higher output of ROS in the local tumor 
environment thereby tipping the scale to a ROS-rich location that promotes tumor cell 
death. The mutant enzyme also has activity towards methionine, which is a key 
component in some human ovarian cancers that are methionine-dependent, as well as a 
key reactant for the generation of glutathionine, which reduces ROS to maintain the 
homeostatic balance [102, 103].  
 In vitro studies were initially conducted as a proof of concept for the efficacy of 
the treatment in ovarian cancer cells showing strong binding of the fusion protein as 
well as cytotoxicity with the addition of the prodrug, selenomethionine. A previous 
study evaluated the cytotoxic nature of the enzyme prodrug on tumor vasculature 
representing endothelial cells as well, since PS is expressed on tumor cells and leaky 
tumor vasculature [25, 116]. 
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 A dosage study was conducted to evaluate the frequency of the enzyme prodrug 
therapy which would provide a decrease in tumor volume while still maintaining 
minimum healthy tissue damage. Treatment every day over a 3 week period yielded the 
largest decrease in tumor volume compared to the saline, untreated mice. Injections of 
mCTH-ANXA5 and SeMet were given 10 h apart to allow for mCTH-ANXA5 blood 
clearance as determined in a previous study [25]. mCTH is a mutant of a mammalian 
enzyme that has minimum activity toward SeMet; however three point mutations 
confers reactivity to SeMet as well as methionine. Some forms of human ovarian cancer 
are considered methionine-dependent tumors, which may prove to be advantageous in 
the clinic as a dual targeting agent to produce cell death initiating ROS as well as 
causing methionine deprivation [102, 103]. Methionine is a key amino acid in the 
protein synthesis as well as de novo pathway, which generates glutathionine to reduce 
ROS and prevent cell damage [102, 103]. The combination of producing ROS as well as 
preventing ROS reduction may have a compounding effect in patients with ovarian 
tumors. 
In order to transition the local tumor environment from an immunosuppressive 
to an immune reactive environment, combinations of anti-PD-1, anti-CD73, and anti-
OX40 immunostimulants were studied to determine the most synergistic immune 
modulation with the enzyme prodrug system.  Upregulation of PD-1 and CD73 
expression have been associated with higher grade ovarian cancer and poor patient 
progression, which makes them key targets for immunotherapy [104, 110]. Clinical 
trials are under way for anti-PD-1 blockade to enhance effector T-cell infiltration and 
inhibit suppressive immune cells for ovarian cancer patients with promising results 
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[105, 117]. Combinatorial studies with anti-PD-1 and anti-OX40 in an ID8 mouse 
model showed promising results of increased survival, decreased tumor burden, and an 
increased immune response compared to either anti-PD-1 or anti-OX40 alone [107]. No 
change in effector or regulatory immune cells were seen with either anti-PD-1 or anti-
OX40 alone; however when combined, there was an increase in the ratio of peritoneal 
infiltrating effector (CD4+ and CD8+ T-cells) versus regulatory (MDSCs and 
CD4+/FoxP3+ T-cells) immune cells [107]. Anti-CD73 is currently undergoing phase I 
clinical trials as well [118]. A study on 4T1 breast tumor models combining anti-PD-1 
with anti-CD73 also had positive outcomes of increased survival and decreased tumor 
burden due to the shift in the ratio of tumor infiltrating cytotoxic T-cells to regulatory 
T-cells [108]. The goal of studying combinations of anti-CD73, anti-OX40, and anti-
PD-1 with the novel enzyme prodrug system was to determine the most effective 
combination with the least distress to animals as well as a minimum toxicity to healthy 
tissue. Combinations of anti-PD-1 with anti-OX40 and anti-CD73 with anti-OX40 
along with the enzyme prodrug system yielded the greatest decrease in tumor volume 2 
weeks post-therapy; however comparing animal distress, mice treated with 
combinations of anti-CD73 and anti-OX40 with the enzyme prodrug system showed 
least animal distress. 
A complete survival and immune response study was conducted comparing 
control, untreated mice against combination therapy mice. The only statistically 
significant increase in survival is seen in mice treated with a combination of the enzyme 
prodrug system with anti-CD73 and anti-OX40. Median survival increased to 57 days 
when compared to the saline treated mice (45 days). No toxicity of the full combination 
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therapy was identified as indicated in the H&E stains of healthy, saline, and full 
combination treated mice. 
In order to determine the mechanism of action of the immunostimulants, 
immune cells from the lymph nodes as well as mouse blood were analyzed to determine 
the impact of a cell-mediated versus an antibody-mediated immune response. Similar to 
previous studies, there was an increasing trend in the presence of cytotoxic T-cells 
while a decrease in regulatory T-cells in mice treated with immunostimulants, either 
with or without the enzyme prodrug system. There is an overall positive shift in the 
ratio of effector to regulatory T-cells, which helps shift the tumor microenvironment 
towards tumor suppression. This shift can be attributed to the co-stimulatory nature of 
the anti-OX40, which helps activate cytotoxic T-cells that recognize foreign antigens 
presented by dendritic cells in the lymph nodes, as well as the blockade of adenosine 
production by anti-CD73. Adenosine acts on adenosine receptors to decrease activation 
of tumor suppressive immune cells while increasing activation of tumor promoting 
immune cells. In mice treated with the enzyme prodrug system along with anti-CD73 
there is an overall increase in the ratio of cytotoxic T-cells to MDSCs, which act as 
tumor promoting cells. There is an overall increase in tumor infiltrating macrophages 
when combining anti-CD73 and anti-OX40. Macrophages can be either M1, anti-tumor, 
or M2, pro-tumor, polarized. Further evaluation will need to be conducted to evaluate 
the difference; however the decrease in tumor burden with the addition of the 
immunostimulants suggests a more anti-tumor environment. An overall decrease in 
tumor suppressive immune cell recruitment is observed in mice treated with either the 
enzyme prodrug system alone or in combination with immunostimulation, which 
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suggests the role of a cell-mediated immune response leading to an increase in survival 
and overall decrease in ovarian tumor burden. 
Although some cell-mediated immunity is observed in mice treated with 
immunostimulants, a more significant synergism is in the antibody-mediated immune 
response. Previous studies combining immunostimulation with various drugs have 
focused on a cell-mediated immune response, but our study has proven a significant 
positive synergism of an antibody-mediated immune response with an ROS generating 
therapy. The addition of anti-CD73 or anti-OX40 caused a slight increase in antibodies 
generated towards the tumor cells compared to either the saline or enzyme prodrug only 
treated mice; however a significant increase in antibodies towards ID8 p53-/- cells is 
seen with the combination of the immunostimulants with the enzyme prodrug system. 
Although a strong antibody response is also seen without the addition of the enzyme 
prodrug system, this response was not enough to cause a significant increase in survival 
or decrease in tumor burden. The combination of the antibody response generated by 
the two immunostimulants and the addition of the ROS inducing tumor cell death is 




This study has shown success in the treatment of metastatic ovarian cancer with a 
combinational approach involving an ROS generating enzyme prodrug system and 
immunostimulation. This therapy can be used to initially treat patients with metastatic 
ovarian tumors as an alternative to surgery and chemotherapy with minimal toxicity to 
healthy tissue as seen in the H&E, or as an option for platinum-resistive patients. The 
combination of the enzyme prodrug system with anti-CD73 and anti-OX40 yielded a 
significant increase in survival (45 – 47.5 days for saline and control mice versus 57 
days for full combination mice), decrease in tumor burden, and increase in an immune 
response against the tumor. In future work, other combinations of immunostimulants 
can be evaluated to determine a more synergistic approach to treat metastatic ovarian 
tumors. Further work can also be conducted into the addition of pyridoxal phosphate, a 
co-factor for the mCTH, with the enzyme prodrug system to increase efficacy of ROS 
generation. Work can also be conducted into evaluating the activity a further mutated 
form of CTH [119, 120]. 
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Chapter V: Mutation of Cystathionine gamma-lyase for Improved 
Activity and Therapeutic Efficacy 
Abstract 
A novel fusion protein, mCGL-ANXA5, has been developed with improved methionase 
activity for the reactive oxygen species (ROS) induced cell death of cancer. The fusion 
protein is a combination of annexin V (ANXA5), which specifically binds to 
phosphatidylserine (PS), and an eight point-mutated mammalian cystathionine gamma-
lyase enzyme (mCGL). The point mutations provide the fusion protein with a three-fold 
increase in methionase activity compared to the original mutant enzyme (mCTH-
ANXA5). The increase in activity is proven beneficial in a proof-of-concept in vitro 
cytotoxicity study with murine breast cancer (4T1) cells causing significant cell death 




A high proportion of tumors are identified once they have become vascularized and 
metastatic. The current standard of care involves a combination of chemotherapy, 
radiation therapy, and surgery, all of which have associated significant side effects and 
nonspecific toxicities. In order to provide a novel alternative, a new mutant form of 
cystathionine gamma lyase (mCGL) fused with annexin V (ANXA5) has been 
developed for the treatment of vascularized solid tumors. ANXA5 binds specifically to 
the phosphatidylserine (PS) exposed on the tumor vasculature and tumor cells [7, 25, 
26, 37]. The fusion protein in combination with the prodrug selenomethionine (SeMet) 
synthesizes methylselenol, a cytotoxic drug, locally at the tumor, thus minimizing side 
effects associated with nonspecific accumulation of current chemotherapeutics [25]. 
This study focuses on the development of a new mutant, mCGL-ANXA5, which 
has more activity than mCTH-ANXA5 previously developed in our lab [25]. The 
increase in activity provides an opportunity to either lower overall dose of the enzyme 
prodrug system or give patients fewer cycles of therapy with the same or better 
therapeutic efficacy, making the novel system more clinically relevant. Characterization 
studies with the new mutant, mCGL-ANXA5, confirm a three-fold increase in overall 
activity compared to mCTH-ANXA5. The increase in activity is further seen in vitro on 




Materials and Methods 
Materials 
pET-30 Ek/LIC vector was from EMD Chemicals (Billerica, MA). Gibson assembly 
master mix was from New England Biolabs (Ipswich, MA). Bovine serum albumin 
(BSA), Alamar Blue reagent, Triton X-100, EDTA, selenomethionine, isopropyl -D-
thiogalactopyranoside (IPTG), and Tris-acetate-EDTA buffer were from Sigma-Aldrich 
(St Louis, MO). HRV-3C protease was from Thermo Fisher Scientific (Waltham, MA). 
Sodium phosphate and sodium dodecyl sulfate (SDS) were from Mallinckrodt 
Chemicals (Phillipsburg, NJ). The 2 and 100 kDa dialysis membranes were from 
Spectrum Laboratories (Rancho Dominguez, CA). Murine breast cancer cells (4T1) and 
RPMI-1640 were from ATCC (Manassas, VA). Fetal bovine serum (FBS) was from 
Atlanta Biologicals (Lawrenceville, GA). Antibiotics, penicillin and streptomycin, were 
from Invitrogen (Grand Island, NY). 
 
Fusion protein construction, expression, and purification 
Eight point mutations were made to wild type human cystathionine gamma-lyase (CTH) 
previously [120]. The same mutations were made to mouse CTH (E58I, S62L, L90M, 
R118L, K267R, P3110G, E338V, and I352S). Mutant mouse CTH (mCGL) and 
annexin A5 (ANXA5) gene fragments were codon optimized for E. coli protein 
production and synthesized (Life Technologies) as three gene fragments (sequences can 
be found in Appendix B: mCGL-ANXA5 Gene Construction). The gene fragments 
were assembled into the pET-30Ek/LIC vector using the Gibson Assembly method  
[121]. Gibson assembly and cell transformation were conducted as previously described 
(more details can be found in Appendix C: Laboratory Protocols
analyzed via DNA electrophoresis as seen in Figure 1
size were sent for sequencing (Oklahoma Medical Research Foundation, Oklahoma 
City, Oklahoma). Protein
parameters as mCTH-ANXA5 production as previously described 
 
 
Figure 15. DNA gel electrophoresis of mCGL
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Fusion protein specificity constant assay 
Enzyme activity with L-selenomethionine was assessed according to the methioninase 
assay previously described [116] with varying concentrations of prodrug. 
 
Cell line and culture conditions 
4T1 cells were grown in RPMI-1640 medium enriched with 10% FBS and 
penicillin/streptomycin antibiotics (100 U ml-1 and 100 µg ml-1, respectively). The cells 
were grown at 37°C with 5% CO2. 
 
Binding strength 
The dissociation constant for mCGL-ANXA5 was determined as previously described 
[25]  using biotin conjugated mCGL-ANXA5 on 70% confluent 4T1 cells. Specific 
binding was determined by subtracting total binding (medium supplemented with 
calcium) from nonspecific binding (medium supplemented with EDTA). 
 
In vitro cytotoxicity studies 
Alamar Blue cell viability assays were conducted to determine the cytotoxic effects of 
mCGL-ANXA5 combined with SeMet on 4T1 cells over 3 days in 24-well plates as 
previously described [25]. 
 
Statistical Analysis 
Statistical significance of in vitro cell survival was assessed using a one-way ANOVA 
and Tukey-Kramer multiple comparisons test with GraphPad Prism software. 
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Results 
Mutant fusion protein characterization 
The new mutant fusion protein, mCGL-ANXA5, was characterized against the original 
mutant, mCTH-ANXA5. The fusion protein, mCGL-ANXA5, had yields of 40 mg l-1 of 
culture medium with > 95% purity. The specificity constant, which is a measure of how 
efficiently substrates are converted into a product by an enzyme, for selenomethionine 
was 1698.03 and 567.96 M-1 s-1 for mCGL-ANXA5 and mCTH-ANXA5, respectively 
(data can be found in Figure 28 of Appendix A: Supplemental Data). The dissociation 
constant (kd) for mCGL-ANXA5 was 0.53 ± 0.16 mM for 4T1 murine breast cancer 
cells (data can be found in Figure 29 of Appendix A: Supplemental Data), which is 
similar to the dissociation constant of mCTH-ANXA5 (0.71 ± 0.48 mM) as previously 
determined [25]. 
 
In vitro cytotoxicity 
The cytotoxic efficacy of the new mutant fusion protein, mCGL-ANXA5, was 
evaluated on 4T1 breast cancer cells as seen in Figure 16. Significant cell death is seen 
after one day of mCGL-ANXA5 and one day of 100 μM SeMet, with increasing 
cytotoxicity as concentrations of SeMet or treatment days increased. 
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Figure 16. In vitro cytotoxicity of the new enzyme prodrug system. 
Cytotoxicity of murine (4T1) breast cancer cells to increasing concentrations of SeMet 
in the presence of mCGL-ANXA5 was determined. Data is presented as mean ± SE (n = 
3). Statistical significance between groups is denoted by * (p < 0.05) and *** (p < 
0.001) with control, untreated cells compared against enzyme prodrug treated cells. 
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Discussion 
The addition of eight point mutations to the mammalian cystathionine gamma-lyase 
enzyme provides it with improved methionase activity compared to the original mutant, 
mCTH-ANXA5, used in the previous chapter. There was a 3-fold increase in the 
specificity constant, which means that the new mutant can bind as well as convert 
selenomethionine into methylselenol more efficiently. The binding strength of mCGL-
ANXA5 was slightly stronger than mCTH-ANXA5, which provides an added 
advantage of stronger association in vivo. 
 In a previous study, the original mutant, mCTH-ANXA5, was evaluated with 
4T1 cells and significant cell death was seen after three days of enzyme prodrug therapy 
[25]. Comparatively, the new mutant caused significant cell death after only one day of 
treatment at the same concentration of fusion protein and SeMet. The overall increase in 
activity renders the new mutant more active in vitro, and may provide a boost in the 
current therapy in vivo by either decreasing the frequency of the therapy needed or 





This study has shown successful synthesis of a novel, mutant fusion protein, mCGL-
ANXA5. The new mutant has eight mutations compared to the original cystathionine 
gamma-lyase enzyme, which makes it three times more active than the previous mutant. 
The increase in activity is advantageous in causing significant breast cancer cell death 
with only one day of enzyme prodrug therapy compared to three days with the other 
mutant. Further evaluation of in vivo cytotoxicity and biocompatibility needs to be 
conducted compared to the previous mutant. 
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Chapter VI: Enhanced MicroCT Imaging via Phosphatidylserine 
Targeted Gold Nanoparticles 
Abstract 
Breast cancer has one of the highest mortality rates usually due to metastatic 
development before primary tumor detection. Mammograms are the current standard of 
diagnosis with annual checkups recommended for women 40 – 54 years of age; 
however due to the low sensitivity and high rate of misdiagnosis patients either are not 
identified during the early stages or they are overdiagnosed and overtreated, sometimes 
leading to radiation-induced tumor development. One of key disadvantages of 
mammograms is their failed ability to differentiate between a dense breast and a tumor 
usually leading to more mammograms and more expensive diagnostic tools such as 
surgery, magnetic resonance imaging (MRI), or positron emission tomography (PET). 
In order to provide a widely available imaging tool for breast cancer, a novel, targeted 
gold nanoparticle (AuNP) has been developed. AuNPs are high density particles that 
increase X-ray attenuation during computed tomography (CT) and can be used for in 
vivo identification of breast cancer. Annexin V (ANXA5) conjugated gold nanoparticles 
(AuNP-ANXA5s) have been developed to specifically bind to phosphatidylserine (PS) 
expressing tumor cells and tumor vasculature. In vitro and in vivo studies showed a 
significant increase in contrast when comparing targeted and untargeted nanoparticles. 
Tumors as small as 4 mm were detectable as early as 4 h post-injection and remained 





Breast cancer is the most common form of cancer for US women with the second 
highest rating for death from cancer. It is estimated that 252, 710 new cases of breast 
cancer will be diagnosed in the US alone in 2017 with 40, 610 deaths [122]. Cancer is 
often detected either during late, untreatable stages or as clinically insignificant tumors 
due to the lack of a highly specific and sensitive detection methodology that can be 
commonly available to the masses for monitoring progression. These rates can be 
significantly reduced if tumors are caught earlier during the pre-malignant. Currently, 
survival rates for patients receiving aggressive treatment before tumor metastasis have a 
94% survival rate. Survival rates fall precipitously to below 10% in late stage, invasive 
tumors [14]. 
The current form of breast cancer detection is annual screening of women 40 – 
54 years via mammograms followed by biopsies and in some instances magnetic 
resonance imaging (MRI). These multiple tests exponentially increase the costs of 
diagnosis for patients. In addition to the monetary costs associated with excessive 
testing, there are significant quality of life costs to repeated screenings. A 10-year 
cumulative study reported overdiagnosis rates as high as 65%. Overdiagnosis results in 
painful invasive screenings and treatments. Up to 77% of women reported pain during 
mammograms, and of these women, 11 – 46% declined further screening. Additionally, 
the high doses of radiation from repeated screenings can increase the risk of developing 
radiation-induced cancer [123]. Currently mammograms are the gold standard of 
diagnosis for women at risk for breast cancer; however they fail to test for differences in 
breast density, which increases costs of diagnosis (follow-up biopsies and MRI), need 
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for repeated screenings, and increases the risk of overdiagnosis and overtreatment. Due 
to this void in accurate early detection of breast cancer, a novel and highly specific 
cancer targeting nanoparticle has been developed for use with computer tomography 
(CT). Using CT is advantageous since it is available in most clinics and hospitals 
around the world for easy implementation and significantly more sensitive than 
mammograms. 
 Gold nanoparticles (AuNPs) have been clinically employed as biosensors, 
immunological assessment tools, drug delivery agents, and in use of disease detection 
and treatment due to their high versatility [124-127]. In vitro as well as in vivo studies 
have proven the nontoxic nature of AuNPs, which are currently in clinical trials as drug 
delivery and photothermal agents [124-129]. We propose the use of targeted AuNPs 
with CT as contrast agents for early detection of breast cancer as a more accurate and 
sensitive alternative to mammograms alone. 
 AuNPs are coated with annexin V (ANXA5), which is a protein that specifically 
binds phosphatidylserine (PS) exposed only on tumor cells and the tumor vasculature 
[7]. PS is internalized in healthy tissue, thus making ANXA5 a specific target for 
multiple cancers including breast cancer [7, 37]. ANXA5 is naturally found in humans 
and mice, making it nontoxic and safe for use. The AuNPs have also been tested 
clinically to be nontoxic and are also coated in polyethylene glycol (PEG), which 
shields the particle from the immune system and prevents toxicity further [130]. 
CT scans, similar to mammograms, distinguish tissues based on attenuation, the 
amount of x-rays that pass through a tissue versus the amount that bounces off the tissue 
and onto the detector. Heavier tissues such as bone attenuate more x-rays onto the 
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detector for a higher contrast while soft tissues such as breast tissue have low 
attenuation, making them hard to distinguish. In order to improve the contrast of tumors 
from the surrounding soft tissue, higher density AuNPs, which attenuate more x-rays, 
are specifically targeted to the malignant region. Unlike mammograms, AuNPs in 
conjunction with CT scans provide higher sensitivity and specificity as well as 
minimize discrepancies in detection due to differences in breast densities. 
 Due to the high density of gold along with the specific targeting ability of 
ANXA5, this study hypothesizes that targeted AuNP-ANXA5s in combination with CT 
can be used as an alternative to identify breast tumors with higher specificity and 
sensitivity. This study has proven the efficacy of increasing contrast of breast cancer 
tissue by 2-3-fold with targeted AuNP-ANXA5s versus untargeted AuNPs in vitro as 
well as in vivo on orthotopic breast (4T1) tumors. AuNP-ANXA5s have a blood 
clearance of 8 h and a tumor residence time up to 96 h, providing a novel tool to track 




Materials and Methods 
Materials 
The plasmid encoding ANXA5, pET-30 Ek/LIC/ANXA5, was previously constructed 
in this lab [64]. Bovine serum albumin (BSA), Alamar Blue reagent, Triton X-100, 
EDTA, sulfo-SMCC, and Tris-acetate-EDTA buffer were from Sigma-Aldrich (St 
Louis, MO). Sodium phosphate is from Mallinckrodt Chemicals (Phillipsburg, NJ). 
Paraformaldehyde was from Electron Microscopy Sciences (Hatfield, PA). Antifade 
reagent Fluoro-gel, borate buffer, fluorescein isothiocyanate (FITC), matrigel, and 
Slide-A-Lyzer dialysis cassettes (3.5 kDa) were from Thermo Fisher Scientific 
(Waltham, MA). The 2 and 100 kDa dialysis membranes were from Spectrum 
Laboratories (Rancho Dominguez, CA). Anti-ANXA5 (FL-319) was from Santa Cruz 
Biotechnology (Santa Cruz, CA). Murine breast cancer cells (4T1) and RPMI-1640 
were from ATCC (Manassas, VA). Fetal bovine serum (FBS) was from Atlanta 
Biologicals (Lawrenceville, GA). Antibiotics, penicillin and streptomycin, were from 
Invitrogen (Grand Island, NY). Gold nanoparticles (15 nm) were from Nanoprobes 
(Yaphank, NY). The 1,2-distearoyl-sn-glycero-3-phosphoethanolaminepolyethylene 
glycol-maleimide (NH2-PEG-SH; PEG molecular weight of 3.4 kDa) linker was from 
Creative PEGWorks (Winston Salem, NC). 
 
ANXA5  production 
Recombinant ANXA5 was produced as previously described [64]. ANXA5 was 




AuNP-ANXA5 was produced in the lab using modified protocols as described [28, 131, 
132]. Briefly, AuNPs (15 nm) were initially conjugated to NH2-PEG-SH at a ratio of 
1:4 (w/w) overnight at 4°C stirring. AuNPs were washed 3X with PBS and centrifuged 
at 16,000 g for 20 min. Sulfo-SMCC was added in a 1:2 (w/w) ratio to the AuNP-PEG 
and incubated for 30 min at room temperature, stirring. The AuNP-PEG-sulfo-SMCC 
was washed 3X with PBS and centrifuged at 16,000 g for 20 min. ANXA5 was added in 
a 1:10 (w/w) ratio and incubated overnight at 4°C followed by 3X washes. The AuNP-
ANXA5s were quantified via absorbance at 520nm (standard curve can be found in 
Figure 30 of Appendix A: Supplemental Data) as well as a Bradford assay. A schematic 
of the AuNP-ANXA5 conjugation is depicted in figure 17 (more details can be found in 





Figure 17. Schematic depicting synthesis of tumor targeted gold nanoparticles 
(AuNP-ANXA5). 
Initially 15 nm gold nanoparticles were coated with PEG (HS-PEG-NH2), a 
biocompatible polymer. Following PEG coating, a linker (sulfo-SMCC) to conjugate 
ANXA5 to the nanoparticle was bound to the PEG with ANXA5 attached to the other 
end. Any unbound PEG, sulfo-SMCC, or ANXA5 was washed off via centrifugation for 
a final product of AuNP-ANXA5. 
 
 
Dynamic light scattering and zeta potential 
Dynamic light scattering (DLS) and zeta potential for AuNP, AuNP-PEG, and AuNP-
ANXA5 nanoparticles was conducted using a Brookhaven ZetaPALS system. Samples 
were diluted in nanopure water for DLS and 1 M KCl solution for zeta potential. 
 
Agarose gel 
A 2% agarose gel in Tris/Borate/EDTA (TBE) buffer was made. Samples were loaded 
and run at 100 V for 1 h. 
 
Transmission electron microscopy 
A drop of either AuNPs or AuNP-ANXA5s was placed on a lacey carbon grid and 
allowed to dry. Both grids were stained with 1% uranyl acetate for 5 min and washed 




Cell lines and culture conditions 
4T1 cells were transfected with tdTomato (Td). 4T1-Td cells were grown in RPMI-
1640 medium enriched with 10% FBS and penicillin/streptomycin antibiotics (100 U 
ml-1 and 100 µg ml-1, respectively). The cells were grown at 37°C with 5% CO2. 
 
In vitro binding strength 
The dissociation constant for AuNP-ANXA5 was determined as previously described 
[64] using biotin conjugated AuNP-ANXA5 on 70% confluent 4T1-Td cells. Specific 
binding was determined by subtracting total binding (medium supplemented with 
calcium) from nonspecific binding (medium supplemented with EDTA). 
 
In vitro fluorescence visualization 
4T1-Td cells were grown to 70% confluence on cover slips. AuNP-ANXA5s were 
tagged with FITC following a protocol by [64]. AuNP-ANXA5-FITCs (1.5 mg ml-1) in 
2 mM CaCl2 were incubated with 4T1-Td cells for 2 h followed with PBS washing. The 
cells were fixed in 4% paraformaldehyde. Images were taken on a Nikon fluorescence 
microscope. 
 
In vitro microCT contrast enhancement 
4T1-Td cells were grown to 70% confluence on a T-75 plate. Cells were lifted and 
incubated with either 1.5 mg ml-1 AuNP or AuNP-ANXA5s in microcentrifuge vials at 
37°C for 2 h. Cells were washed 3X with media and centrifuged at 1000 g for 5 min 
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followed by fixation with 4% paraformaldehyde. Images were taken on a PerkinElmer 
Quantum GX microCT (Waltham, MA) at 50 keV. 
 
Animal handling procedures 
All procedures complied with a protocol approved by Institutional Animal Care and Use 
Committee (IACUC) of the University of Oklahoma Health Sciences Center. Balb/cJ 
female mice 6 weeks of age, weighing 18 – 20 g were used. Mice were on a standard 
chow diet. 
 
In vivo tumor model 
Mice were injected in mammary fat pad number four with 1 x 105 4T1-Td mouse breast 
cancer cells suspended in 50 µl PBS and 50 µl of matrigel. Mouse body weight and 
tumor volume were monitored every 3 to 4 days. Tumor volume was calculated with the 
modified ellipsoid formula volume = (1/2) x (length x width2) using caliper 
measurements of the longest dimension and perpendicular width. Mice bearing 
orthotopic 4T1-Td were randomized into groups (6 to 7 per group) prior to the start of 
the study when tumors reached 100 mm3. 
 
In vivo blood clearance 
Blood clearance was determined based on a modified protocol from [25]. Briefly, 
AuNP-ANXA5s were tagged with biotin following the SeraCare company protocol. 
Blood was collected from mice (n = 3) between 0 – 24 h and analyzed via an ELISA 
sandwich assay using streptavidin coated high-affinity plates. Plasma dilutions were 
98 
incubated on strepatavidin coated plates for 2 h at 37°C.  Plates were washed and 
blocked with 1% fetal bovine serum PBS buffer three times. Following washes, wells 
were incubated for 1 h with 1:5000 dilution of HRP conjugated goat anti-mouse IgG 
and IgM. The wells were developed with o-phenylenediamine (OPD) for quantification 
on a BioTek Synergy plate reader (more details can be found in Appendix C: 
Laboratory Protocols). 
 
In vivo targeted binding affinity 
Mice (n = 6-7) were injected with 250 mg kg-1 AuNP or AuNP-ANXA5 intravenously 
when tumors reached 100 mm3. Mice were imaged with Flex X-O X-PET (Gamma 
Medica Ideas, Northridge, CA) animal imager at 50 keV with 256 slices before the 
injection and for 96 h after. Gold concentration was determined by quantifying CT 
intensity at the tumor against the control image using the Amira software. Intensity was 
correlated to a gold standard curve previously generated (standard curve can be found in 
Figure 31 of Appendix A: Supplemental Data). 
 
Statistics 
Statistical significance of in vitro and in vivo contrast enhancement studies was assessed 




Characterization of AuNP-ANXA5s 
Multiple analysis (UV-vis spectroscopy, agarose gel, DLS, and zeta potential) were 
conducted on the particles confirming that the addition of ANXA5 as well as the 
maintenance of the key characteristics of AuNPs that makes it a contrast agent. Analysis 
via UV-vis spectroscopy was conducted, ensuring that the particle retained its 
characteristic properties as seen in the similar absorbance spectrums in figure 18a of 
AuNP against AuNP-ANXA5. 
Table 3 further depicts the transition in size and surface modification of the 
particle as seen in the increasing hydrodynamic diameters (AuNP < AuNP-PEG < 
AuNP-ANXA5) of the particles. The surface charge of the nanoparticle also changes 
with the addition of PEG and ANXA5 as seen in the zeta potential in table 3. Since 
ANXA5 is a negatively charged protein, the surface of the nanoparticle becomes more 
negative with the addition of ANXA5 as compared to the particle only coated in PEG. 
Another key feature to evaluate the conjugation of ANXA5 to the surface of 
AuNPs was assessed on an agarose gel. An agarose gel allows nanomaterials to move 
through a gradient based on size. Smaller particles, such as AuNP, travel further down 
the gel while larger particle, such as AuNP-ANXA5, travel slower. As seen in figure 
18b, AuNP moved the furthest, followed by AuNP-PEG and finally AuNP-ANXA5. 
A final characterization was conducted to visualize the nanoparticles coated in 
ANXA5 protein. Transmission electron microscopy (TEM) with staining for protein 
presence was conducted on AuNP and AuNP-ANXA5. Figure 18c shows individual 
gold nanoparticles (dark black circles) with the ANXA5 protein (hazy, dark gray 






Figure 18. Characterization of AuNP-ANXA5. 
(a) Absorbance spectrum of gold nanoparticles showing no change in primary 
characteristics, which would affect the CT enhancement property of the particle, with 
the addition of PEG or ANXA5. (b) An agarose gel confirming surface modification of 
AuNPs. Smaller particles, such as AuNP, move further and fast through the gel, while 
larger particles, such as AuNP-ANXA5, more slower down the gel. (c) A transmission 
electron microscopy image of single gold nanoparticles (dark black circle) coated with 
ANXA5 protein (hazy, dark gray region). Scale bar is 15 nm. 
 
 
Table 3. DLS and zeta potential of AuNP-ANXA5. 
Confirmation of the surface modification of AuNPs with PEG and ANXA5 as seen in 
changes of the hydrodynamic diameter of the particle increasing with each addition of 
PEG and ANXA5. The surface charge of the nanoparticle (zeta potential) is also altered 
with the addition of PEG which makes the surface more neutral to act as a shield against 
the immune system in vivo. While the addition of ANXA5, which is a negatively 
charged protein, makes the particle surface slightly more negative, confirming binding 
of ANXA5 to the surface. Data represented as mean ± SEM (n = 3). 
 
In vitro confirmation 
Binding was further tested by incubating 4T1 breast cancer cells with AuNP or AuNP-
ANXA5 followed by CT via a PerkinElmer Quantum GX microCT (Waltham, MA) as 
seen in figure 19a. Breast cancer cells that were incubated with only AuNP had only a 
~2-fold increase in contrast compared to cells with no nanoparticles. Cells incubated 
with AuNP-ANXA5 had a ~4-fold increase in contrast. This study provides significant 
evidence of the benefit of using
detection of cancer cells for early detection. The bind
specifically to 4T1 breast cancer cells 
32 of Appendix A: Supplemental Data)
localization of FITC labeled 
4T1 breast cancer cells. 
 
Figure 19. In vitro binding specificity of AuNP
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 targeted gold nanoparticles to enhance the X
ing of the AuNP-ANXA5
was 60.31 ± 68 pM (data can be found in Figure 
. This can be visualized in figure 19




b with the 
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(a) 4T1 breast cancer cells (n = 1) were incubated with either AuNP or AuNP-ANXA5 
(1.5 mg ml-1) for 2 h followed by washing of any unbound nanoparticles. Cells were 
imaged via CT and difference in contrast was evaluated. The addition of untargeted 
AuNPs causes a slight increase in contrast of cells; however a significant increase in 
contrast is seen in cells incubated with targeted nanoparticles (AuNP-ANXA5s). The 
images above the graph are representative of the cells incubated with each nanoparticle. 
The cells incubated with AuNP-ANXA5s visibly look more pink due to the 
accumulation of the gold nanoparticles. (b) Fluorescent microscopy showing 
localization of tdTomato labeled 4T1 cancer cells (left) and FITC-labeled AuNP-
ANXA5 (right). Scale bar is 25 μm. 
 
In vivo confirmation 
An animal study on mice with orthotopic 4T1 breast tumors in the mammary fat pad 
was conducted to determine how long the AuNP-ANXA5s remained in the blood. As 




Figure 20. Blood clearance. 
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Balb/c mice (n = 3) were injected with biotinylated AuNP-ANXA5s, and blood was 
collected between 10 mins to 24 h post-injection. After 8 h, no AuNP-ANXA5s were 
detectable in the blood of mice. 
 
A second animal study comparing targeted versus untargeted gold nanoparticles 
was conducted to evaluate the clinical relevance of using AuNP-ANXA5s for detection 
of breast cancer. Mice were injected intravenously (i.v.) with 250 mg kg-1 (5 mg) of 
either AuNPs or AuNP-ANXA5s, and CT scans were conducted via a Flex X-O X-PET 
(Gamma Medica Ideas, Northridge, CA) system over time to compare tumor 
accumulation of nanoparticles.  
 Figure 21 shows representative CT images of mice with small 4T1 breast tumors 
12 h after delivery of either AuNP (figure 21a) or AuNP-ANXA5 (figure 21b). When 
comparing the tumors before injection of nanoparticles versus after, the mice injected 
with AuNP-ANXA5s have a strong, bright border around the rim of the tumor (white 
arrows) where the gold nanoparticles have accumulated in the tumor as well as on the 
tumor vasculature. On the other hand, the untargeted AuNPs injected mouse has 
minimum increase in contrast. 
 
Figure 21. Representative CT images (xz cross section) of Balb/c mice with 4T1 
breast cancer tumors. 
Mice were imaged before and 
(b) AuNP-ANXA5s. (a) 
tumor compared to the remainder of the animal. 
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12 h after injection of either 250 mg kg-1 
In the mouse injected with AuNPs it is difficult to identif
(b) In the mouse injected with 
  
 




ANXA5s, a clear border of the tumor is significantly brighter (white arrows) where the 
gold nanoparticles have accumulated. 
 
 The images in figure 21 were taken for multiple mice (n = 6-7) injected with 
either AuNP or AuNP-ANXA5 and analyzed for accumulation of gold nanoparticles at 
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Equation 2. Injected dose calculation. 
Concentration of AuNP or AuNP-ANXA5 at the tumor was calculated with a pre-
determined standard curve comparing change in contrast to concentration of gold 
nanoparticles.  
 
As seen the Figure 22, tumors of mice with AuNP-ANXA5 had significantly 
higher accumulation of nanoparticles compared to untargeted nanoparticles starting as 
early as 4 hours and continuing for 96 hours. There is ~2-3-fold increase in 
concentration of gold nanoparticles when comparing targeted versus untargeted 
nanoparticles. The contrast remained for up to 96 h which can be further advantageous 
clinically as a means of monitoring tumor progression during rounds of chemotherapy 
to evaluate the real-time efficacy of the treatment. 
 
Figure 22. Binding specificity of targeted versus untargeted AuNPs 
Mice with orthotopic breast cancer (4T1) tumors 
AuNP-ANXA5s and imaged over a 96 hour period to evaluate accumulation at the site 
of the tumor. A dose of 250 mg kg
than the LD50 (5000 mg kg
during the course of the study. Mice injected with 
accumulation of nanoparticles as compared 
after. The sharp difference in accumulation remains throughout the remainder of the 
study with increasing amounts of the injected dose accumulating at the tumor and 
remaining there until at least 96 hours post inj
(n = 6 – 7). Statistical significance indicated as ** (p < 0.01).
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were injected with either AuNPs or 
-1 was given per animal, which is significantly lower 
-1). No signs of mouse stress or toxicity were detected 
AuNP-ANXA5s had significant 
to AuNPs injected mice as early as 4 hours 








Breast cancer has a 94% survival rate if diagnosed early on; however when diagnosed 
during late stage, survival falls to only 10% [14, 122]. Mammograms are the current 
gold standard for breast cancer diagnosis with up to a 65% misdiagnosis rate, usually 
due to the failure of differentiating tumors from dense breasts [14, 122]. A novel 
targeted gold nanoparticle has been developed with computed tomography as an 
alternative to diagnosis of breast cancer earlier and with more specificity. Gold 
nanoparticles are conjugated to annexin V, which binds specifically to 
phosphatidylserine exposed on tumor cells and tumor vasculature. CT, a widely 
available imaging modality, can be used to detect presence of breast cancer with higher 
sensitivity and specificity than the current standard of care. 
Targeted gold nanoparticles were developed and characterized using DLS, zeta-
potential, UV-vis spectroscopy, and TEM. Changes in the hydrodynamic diameter and 
zeta potential confirmed addition of PEG and ANXA5 to the surface of gold 
nanoparticles. PEG acts a protective polymer shielding the gold nanoparticles from the 
immune system by minimizing recognition as seen in the more neutral zeta-potential of 
the gold nanoparticles. ANXA5 is a negatively charged protein which causes a negative 
shift in the PEG coated gold nanoparticles as well as an increase in the hydrodynamic 
diameter. 
In vitro studies showed specific binding of AuNP-ANXA5 to 4T1 breast cancer 
cells via fluorescent microscopy and microCT imaging. The addition of AuNPs caused 
a 2-fold increase in contrast, while the addition of AuNP-ANXA5 increased contrast by 
4-fold compared to breast cancer cells only. In vivo studies confirmed plasma clearance 
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of AuNP-ANXA5s within 8 h post-injection and tumor identification as soon as 4 h 
after injection. AuNP-ANXA5s had a 2-3-fold increase in contrast compared to control 
AuNPs, which lasted for 96 h post-injection. Tumors as small as 4 mm were 
identifiable, making AuNP-ANXA5 a promising modality for early diagnosis of breast 
cancer compared to the 10 – 20 mm detection limit of mammograms [27]. The AuNPs 
have an LD50 of 100 mg (5000 mg kg-1) per animal as evaluated by the company 
(Nanoprobes Inc.). Doses as high as 1100 mg kg-1 have been tested in mice with no 
detectable toxicity [28]. Our dose of 5 mg per animal (250 mg kg-1) is significantly 
lower than the cytotoxic dose. 
Recent studies using targeted gold nanoparticles showed similar increases in 
contrast in vitro and in vivo against larynx and oral cancer, glioblastoma, and lymph 
nodes as compared to untargeted nanoparticles [28, 133-136]. Compared to other 
targeted nanoparticles, a key advantage of the proposed technology is the broad 
applicability for detection of multiple cancers, such as bladder, ovarian, melanoma, and 
lung, which do not have effective diagnosis modalities that are sensitive as well as 
widely available to the general public. Current diagnosis tools require expensive and 
scarcely available tools such as MRI or PET systems with the risk of still getting false 
positives and negatives. Due to a lack of a cost-effective and widely available imaging 
modality, most patients are diagnosed during late stages of tumor development at which 
point the effectiveness of surgery and chemotherapy has significantly decreased. The 
proposed technology can be further expanded as an alternative for the universal 
detection of multiple cancers using computed tomography (CT), which is already 
widely present in all clinics and hospitals.  
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Conclusions 
The use of AuNP-ANXA5, a novel, targeted contrast agent for early detection of breast 
cancer, in conjunction with computed tomography can provide an alternative cost-
effective diagnosis tool with more precision and accuracy for multiple malignancies 
including breast cancer. We have developed and evaluated the efficacy of AuNP-
ANXA5s in cell culture as well as in animal models showing significant increases in 
detection of breast tumors with targeted versus untargeted gold nanoparticles. Gold 
nanoparticles have minimum toxicity and are currently being tested in phase I clinical 
trials for therapy based applications [128, 129]. Combined with ANXA5, which is a 
naturally occurring human protein, the targeted nanoparticle contrast agent has the 
capability of being a universal diagnosis tool for early cancer detection of multiple 
malignancies (breast, ovarian, melanoma, bladder, etc). 
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Chapter VII: Conclusions and Future Directions 
A large group of patients with cancer are either diagnosed once metastasis has occurred 
or have relapsed with chemoresistive tumors. In order to treat as well as diagnose these 
patients, novel biotechnology agents needs to be developed. This thesis proposes the use 
of annexin V (ANXA5) conjugated agents for the novel treatment and diagnosis of 
bladder, ovarian, and breast cancer. ANXA5 is a mammalian protein that specifically 
interacts with phosphatidylserine (PS), which is expressed by the tumor vasculature and 
multiple cancer cells [7, 37]. The interaction between ANXA5 and PS can be used to 
target therapeutic biotechnology agents, such as single-walled carbon nanotubes 
(SWCNT-AVNXA5) and enzyme prodrug systems (mCTH-ANXA5 and mCGL-
ANXA5), for local treatment of tumors while minimizing nonspecific accumulation and 
toxicity of these agents, which is a key limiting factor for most chemotherapeutic drugs. 
Although current chemotherapeutics are effective in treating low stage tumors at high 
doses, the damage to healthy tissue due to nonspecific accumulation often outweighs 
the therapeutic efficacy thus limiting their use. ANXA5 can also be used to target 
imaging agents such as gold nanoparticles (AuNP-ANXA5) to tumors for enhanced 
early detection of breast cancer as well as other PS expressing tumors. This thesis 
focused on the development and assessment of three PS-targeted biotechnology agents 




Single-walled carbon nanotubes 
Single-walled carbon nanotubes (SWCNTs) can generate heat by two key mechanisms: 
1) absorbing light in the near-infrared (NIR) region, specifically 980 nm, and 
dissipating their energy as heat and 2)  generating dipole moments in a radiofrequency 
(RF) field and generating vibrational energy that leads to heat dissipation. Chapters II 
and III focus on the efficacy of PS targeted SWCNT-ANXA5s as photothermal ablation 
agents for cancer therapy. 
 SWCNT-ANXA5s at very low doses (0.1 mg SWCNTs kg-1) are delivered 
intravesically into the bladder of mice with orthotopic murine bladder cancer (MB49) 
and treated for a short period (30 sec) with a global NIR light (power density of 1.7 W 
cm-2). After one cycle of therapy, there was a 50% survival rate with no recurrence of 
bladder cancer for 116 days at which point the study was ended. No nonspecific 
accumulation of SWCNT-AVs was detected in any clearance organs or the bladders of 
treated mice, and no short-term or long-term toxicity was identified. 
Due to the relative safety of the photothermal approach, future work can be 
conducted on a multi-cycle therapy to increase the survival rate and decrease recurrence 
rate of bladder cancer. The photothermal approach can be further enhanced with 
inhibitors of heat shock proteins (HSP), which are activated as a defense mechanism in 
healthy and cancer cells to promote survival and resistance [137]. A previous study 
showed strong synergism between a heat-based therapy and HSP inhibitors with 
significant increase in overall survival [138]. The photothermal therapy can also be 
combined with chemotherapy drugs for improved survival since nanotubes can be 
effective drug delivery vehicles [139-141]. The addition of chemotherapeutic drugs 
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such as docetaxel and doxorubicin provides a means of a multi-pronged treatment, a 
higher payload of drug delivery, and a more targeted chemotherapeutic drug delivery 
system that may reduce nonspecific side effects associated with free, untargeted drugs. 
 Although SWCNT-ANXA5s in conjunction with NIR is effective at treating 
non-muscle invasive bladder cancer, this therapy can be further expanded into deeper 
tumors that are less accessible using radiofrequency (RF). RF can also cause SWCNT-
ANXA5 heating, which can be further enhanced if the appropriate resonance frequency 
is applied. Chapter III of this thesis focuses on preliminary studies to determine the 
appropriate resonance frequency of SWCNT-ANXA5s since RF can deeply penetrate 
tissue to treat cancers, such as bone, brain, and liver tumors. Future work to determine 
the resonance frequency can be determined; however even at 45 MHz the rate of 
heating of SWCNT-ANXA5s is significantly higher than NIR heating, which already 
causes tumor cell death as seen in Chapter 2. Evaluation of in vitro and in vivo 





Enzyme prodrug system 
A novel mammalian fusion protein (mCTH-ANXA5) was developed previously with 
specific binding to PS expressing tumor cells and vasculature via ANXA5, as well as 
methionase activity for the conversion of a nontoxic prodrug, selenomethionine 
(SeMet), into a toxic, reactive oxygen species (ROS) generating drug, methylselenol 
[25]. Most patients with ovarian cancer are diagnosed once metastasis has occurred with 
a portion quickly developing platinum-resistive tumors. In order to provide an 
alternative, an enzyme prodrug system (mCTH-ANXA5) was developed for treatment 
and combined with immunostimulation for a synergistic approach in Chapter IV. The 
enzyme prodrug system delivered every day for 21 days provided a decrease in overall 
tumor burden two weeks post-therapy. This decrease was further enhanced with the 
addition of anti-CD73, which blocks CD73 receptors on cancer cells and prevents 
production of adenosine, and anti-OX40, which is a T-cell activating co-stimulatory 
antibody. The addition of both immunostimulants increased median survival from 45 
days for saline treated mice to 57 days as well as decreased final tumor burden. The 
synergism of the enzyme prodrug system and immunostimulation is seen in the 
increases in cell- and antibody-mediated immune responses. There is an overall increase 
in the ratio of effector immune cells compared to regulatory immune cells in the 
mesenteric lymph nodes as well as a significant increase in tumor specific antibodies. 
The enzyme prodrug system can be further improved by testing other 
combination of immunostimulants such as anti-PD-1 or anti-CTLA-4, both of which are 
currently in clinical trials. The dose and frequency of the immunotimulants alone and in 
combination with the enzyme prodrug system can also be optimized to reduce the 
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number of cycles of therapy, making it more clinically relevant. Since ROS induces cell 
death by causing DNA damage, alkylation agents such as cyclophosphamide or 
cisplatin can be tested that would prevent the cancer cells from repairing their damaged 
DNA and increase synergism. Pyridoxal-5’-phosphate (PLP), which is a cofactor of 
mCTH and has proven to increase the half-life of methionase from 1.5 to 7 h, and can 
be added to increase the efficacy of the therapy and decrease frequency of cycles 
needed. PLP dosage and frequency of delivery can also be optimized to prevent 
unbound and any nonspecifically accumulated mCTH-ANXA5 from causing healthy 
tissue damage. Currently, mCTH-ANXA5 is delivered intraperitoneally (i.p.), which 
can easily diffuse molecules under 20 kD [142]. mCTH-ANXA5 is 320 kD, which 
limits its diffusion across the peritoneum and into blood circulation for efficient 
targeting of PS expressing tumor vasculature. Future studies can compare delivery of 
mCTH-ANXA5 and effectiveness of therapy between i.p. and intravenous (i.v.) 
injections. 
 Another possibility to improve the overall survival and decrease tumor burden is 
to deliver a more active form of mCTH-ANXA5. Chapter V focuses on the 
development of a novel mutant of cystathionine gamma-lyase (mCGL-ANXA5) with 
eight new point mutations; the result was an increase in methionase activity by three-
fold compared to mCTH-ANXA5. The improved fusion protein can be tested in vivo 
against the original mutant for changes in overall tumor burden as well as differences in 
dosages of the enzyme prodrug system needed to achieve similar efficacies. Due to the 
increase in mutations, mCGL-ANXA5 may be more immunogenic then mCTH-
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ANXA5. Antibody titers and toxicity analysis can be conducted to determine the 




A key to effective cancer treatment is early cancer detection. The current gold standard 
for breast cancer diagnosis is a mammogram; however mammograms have a high false 
positive rate [14]. This rate can be decreased with the use of targeted contrast agents 
such as PS specific gold nanoparticles (AuNP-ANXA5). AuNP-ANXA5 increases 
contrast of tumors as small as 4 mm compared to untargeted gold nanoparticles using 
computed tomography (CT) as seen in Chapter VI. 
A dose of 250 mg kg-1 AuNP-ANXA5 had a 2-3 fold increase in contrast as 
early as 4 h post-injection. Although the injected dose is 20 times lower than the LD50 
of 5000 mg kg-1 as reported by the gold nanoparticle manufacturer (Nanoprobes), 
further optimization of dosage can be conducted to determine the lowest dose needed to 
achieve tumor contrast with minimal nonspecific accumulation and toxicity. A key 
problem with mammograms today is the difficulty in differentiating a dense breast or a 
breast with microcalcifications from a breast tumor. Since AuNP-ANXA5 specifically 
binds PS exposed on tumor cells and the tumor vasculature, targeted gold nanoparticles 
can be tested as novel agents with increased specificity and sensitivity to differentiate a 
tumor from a microcalcification or dense breast. 
Work in this thesis with the gold nanoparticles has focused on breast cancer; 
however as seen in the previous chapters and literature, tumors such as bladder, ovarian, 
liver, and renal cancer also express PS with no efficient means of mass screening [7, 
37]. Future work can focus on developing the versatility of AuNP-ANXA5 as a 
universal contrast agent for routine screenings using a CT, which is already widely 
available in most clinics and hospitals. Similar to SWCNTs, gold nanoparticles have 
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also been used as drug delivery vehicles [143-145]. AuNP-ANXA5 can be further 
expanded to be a multi-modal nanoparticle for detection as well as therapy by 
delivering cytotoxic drugs directly to the tumor. However, since the optimal AuNP-
ANXA5 dose for imaging is likely to be different from that for cytotoxic drug delivery, 
it may be necessary to use AuNP-ANXA5 for imaging and a AuNP-ANXA5 drug 




Phosphatidylserine targeting biotechnology agents 
All three PS-targeting biotechnology agents were effective in preventing systemic 
toxicity due to their specificity to the tumor via ANXA5. Although this thesis has 
focused each agent on one cancer, PS is expressed in multiple tumors and the tumor 
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Figure 24. In vitro cytotoxicity of SWCNT
Murine (MB49) or human (J82) bladder cancer cells were in
SWCNT-ANXA5 for 2 h at 37°C. Cells were washed three times with media followed 
by 30 sec of NIR treatment at 50 J cm
respectively. Data presented at mean ± SEM
* (p < 0.05). 
 
Figure 25. Standard curve for SWCNT
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Figure 26. Schematic of RF system and matching network.
In order to determine the resonance of nanotubes within the RF range as well as run 
vitro cytotoxicity studies, a RF and matching networks needs to b
the proposed system is presented here.
 
 
Figure 27. Binding strength data of mCTH
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Figure 28. Michaelis-Menten kinetics.
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Figure 29. Binding strength data of mCGL-ANXA5 for breast cancer cells. 
Specific binding was determined by subtracting total binding in Ca2+ supplemented 
media from nonspecific binding in EDTA supplemented medium for 4T1 cells. Binding 
was quantified with biotinylated mCGL-ANXA5 and HRP-conjugated streptavidin, 
developed with OPD. Data are presented as mean ± SEM (n = 3). 
 
 
Figure 30. Standard curve for AuNP concentration. 
Absorbance of AuNP was measured at 520 nm at various concentrations to determine 
the standard curve for AuNPA-ANXA5 concentration determination. 
 
Figure 31. Standard curve for AuNP
intensity. 
The CT intensities for various concentrations of AuNP
keV. 
 
Figure 32. Binding strength data of AuNP
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Appendix B: mCGL-ANXA5 Gene Construction 

















































































































































Appendix C: Laboratory Protocols 
FIJI macro for bladder tumor quantification 
//This macro quantifies the TdTomato fluorescence on a mouse bladder with respect to 
bladder area  
//The macro assumes the files are ".tif" images of a bladder from a dissection scope 
imaged for Tdtomato 
 
//Close all current images 
close("*"); 
 
//Clear results table 
run("Clear Results"); 
 
//Choose the input directory for Tdtomato Fluorescent images 
TRDirectory = getDirectory("Choose Fluoresence input directory"); 
 
//Get all filenames in directory and store in an array 
TRfileList = getFileList(TRDirectory); 
 
//Choose the output directory for the processed images and final analysis excel file 
outputDirectory = getDirectory("Choose output directory"); 
 
//Set which measurements to collect: area, integrated density, and mean gray value 
run("Set Measurements...", "area mean integrated redirect=None decimal=3"); 
 
//Overall image processing to all images one at a time 
for (a=0; a<TRfileList.length; a++) { 
 //Open fluorescent image and get title 
 open(TRDirectory + TRfileList[a]); 
 TRfile = getTitle(); 
  
 //Remove measurement units since there is no scale associated with these 
images 
 //Program sets a default scale in inches which is incorrect for these images 
 run("Properties...", "channels=1 slices=1 frames=1 unit=pixel pixel_width=1 
pixel_height=1 voxel_depth=1 global"); 
 //Convert to an 8-bit from an RGB image to run further analysis 
 run("8-bit"); 
 //Save converted image 
 TRfile_Scaled = replace(TRfile, ".tif", "_Scaled.tif"); 
 saveAs("tiff", outputDirectory + TRfile_Scaled); 
  
 //Remove dark current noise in image from camera and save image 
 run("FeatureJ Derivatives", "x-order=0 y-order=0 z-order=0 smoothing=4"); 
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 TRfile_Scaled_NoNoise = replace(TRfile, ".tif", "_Scaled_NoNoise.tif"); 
 saveAs("tiff", outputDirectory + TRfile_Scaled_NoNoise); 
  
 //Threshold image using Huang algorithm to get mask of bladder and save 
thresholded image 
 run("Threshold..."); 
 setAutoThreshold("Huang dark"); 
 //Some images do not auto thershold properly so this allows user to adjust 
thershold 
 waitForUser("Adjust threshold value. \nClick OK when complete."); 
 //By not selecting "BlackBackground", the object is assumed to be black and 
background white 
 setOption("BlackBackground", false); 
 //Generates a binary mask of the thresholded image 
 run("Convert to Mask"); 
 TRfile_Scaled_NoNoise_Threshold = replace(TRfile, ".tif", 
"_Scaled_NoNoise_Threshold.tif"); 
 saveAs("tiff", outputDirectory + TRfile_Scaled_NoNoise_Threshold); 
 
 //Closed 8-bit image 
 close("*_Scaled.tif"); 
 
 //Get mask of only bladder and save mask 
 //Only the bladder area will be measured since it is the only object that fits in the 
 //size range selected (largest object) 
 run("Analyze Particles...", "size=100000.00-Infinity show=Masks"); 
 TRfile_Scaled_NoNoise_Threshold_Mask = replace(TRfile, ".tif", 
"_Scaled_NoNoise_Threshold_Mask.tif"); 
 saveAs("tiff", outputDirectory + TRfile_Scaled_NoNoise_Threshold_Mask); 
 
 //Close Threshold image 
 close("*_Scaled_NoNoise_Threshold.tif"); 
 
 //Create selection of mask and paste on original fluorescent image  
 run("Create Selection"); 
 //Reopen original fluorescent image 
 open(TRDirectory + TRfileList[a]); 
 //Paste mask on original fluorescent image for quantification 
 run("Restore Selection"); 
  
 //Measure area, mean, and integrated intensity 
 run("Measure"); 
 
 //Add name to row to keep track of what results go with what image 
 setResult("Sample", a, TRfile); 
 updateResults(); 
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//Save measurements in results window to excel file in output directory 
selectWindow("Results"); 







Flow Cytometry Staining 
Tissue Collection: 
1. Euthanize animal with CO2 inhalation. 
2. Collect blood and place in heparin tube. Spin tube to separate plasma from blood 
and store at -20°C. 
3. Collect lymph node and spleen and place in 5 ml of cold RPMI-1640 medium. 
Place samples on ice and transport to Norman. 
4. Collect remaining tissue (liver, kidney, heart, lungs, intestine, and tumor) place 
in 10% NBF. 
Flow Cytomery Buffer Preparation: 
1. Flow Cytometry Staining Buffer (SB): 1X PBS + 0.5% BSA + 0.05% Sodium 
Azide. 
2. Foxp3 Fixation/Permeabilization working solution: Dilute the 
Fixation/Permeabilization Concentrate (1 part) with Fixation/Permeabilization 
Diluent (3 parts). You will need 1 mL of the Fixation/Permeabilization working 
solution for each sample, if staining in tubes. 
3. Permeabilization Buffer: Dilute the 10X concentrate with distilled water prior to 
use. 
All following procedures with cells should be conducted on ice. 
Flow Cytometry Sample Preparation: 
1. Tease apart tissue (lymph node and spleen) into a single-cell suspension by 
pressing with the plunger of a 3-mL syringe with 1 ml of SB into a petri dish. 
Wash plunger 2X with 1 ml SB each time. 
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2. Place a cell strainer on top of a 50-ml conical tube. Pass cells from the petri 
culture dish through the cell strainer to eliminate clumps and debris. Wash petri 
dish and stainer 2X with 1 ml SB each time. 
3. Centrifuge cell suspension at 300-400g for 4-5 min at 2-8°C. Discard the 
supernatant. 
4. Resuspend the cell pellet in a 1 ml volume of SB and perform a cell count and 
viability analysis. 
a. Add 10 μl of typan blue + 10 μl of diluted cell suspension (1:100 
dilution) and count live and total cells. 
5. Centrifuge cells as in Step 3 and resuspend in appropriate volume of SB so that 
the final cell concentration is 1 x 107 cells ml-1. 
 
Flow Cytometry Staining 
1. Add 100 μL of cell stock to a 2 mL microvial. 
2. Spin primary antibody tubes to pull solution to bottom of vial. 
3. Stock antibody cocktail 
4. Add stock antibody cocktail (Table 1) and bring final volume to 50 μl with SB. 
5. Incubate for at least 60 minutes at 2-8°C or on ice. Protect from light. 
6. Wash the cells by adding Flow Cytometry Staining Buffer. Use 2 ml tube-1. 
Centrifuge at 400-600g for 5 min at room temperature. Discard supernatant. 
7. Repeat previous wash step. 
8. Add 1 ml of Fixation/Permeabilization working solution to each tube and pulse 
vortex. 
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9. Incubate for 60 min at room temperature. Protect samples from light. 
10. Wash the cells by adding 1X Permeabilization Buffer to each tube. Use 1 ml 
tube-1. Centrifuge at 400-600g for 5 min at room temperature. Discard 
supernatant. 
11. Repeat previous wash step. 
12. Resuspend pellet in 100 μl of 1X Permeabilization Buffer. This is typically the 
residual volume after decanting. 
13. Block with 2% BSA by adding 2 μl directly to the cells. 
14. Incubate for 15 min at room temperature. 
15. Without washing, add either 2.5 μL of PE-Foxp3 antibody or SB (Table 1) to 
cells. 
16. Incubate for at least 30 minutes at room temperature. Protect samples from light. 
17. Wash the cells by adding 1X Permeabilization Buffer to each tube. Use 1 ml 
tube-1. Centrifuge at 400-600g for 5 min at room temperature. Discard 
supernatant. 
18. Repeat previous wash step. 
19. Resuspend cells in an appropriate volume of Flow Cytometry Staining Buffer. 




1) Mice were euthanized 3 days after immunostimulation and blood was collected 
in heparin tubes. 
a. Allow 20 min for clots to form before centrifugation 
b. Centrifuge at 3500g for 90 s. 
c. Remove serum with pipet and freeze (cryovial) at -80°C. 
2) Plate ID8 p53-/- cells at 70% confluence on 96-well plates. 
3) Buffers: 
a. Diluting Buffer (1 L) 
i. 0.5 g Tween 20 (0.005%) 
ii. 2.5 g BSA (0.25%) 
iii. 1 l PBS 
b. Wash Buffer 
i. 5 g Tween 20 (0.05%) 
ii. 1 l PBS  
4) Add 50 µ of each serum sample to wells. Make appropriate dilutions. 
5) Cover the plate with adhesive cover and incubate for 2 h at 37°C 
6) Shake out the plates into a sink. Wash the plates with wash buffer 4 times by 
adding 200 µ and shaking out the wash buffer into a sink. Pat plates dry by 
inverting on paper towel. 
7) Add 50 µl of anti-rabbit IgG-HRP conjugate (secondary antibody) diluted to 
1:5000 (initially at about 1 mg/mL) using diluting buffer to each well. 
8) Cover the plate with adhesive cover and incubate for 60 min at 37°C. 
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9) Shake out the plates into a sink. Wash the plates with wash buffer 4 times by 
adding 200 µl and shaking out the Wash buffer into a sink. Pat plates dry by 
inverting on paper towel. 
10) Prepare a curve in blood/serum of different dilutions of anti-rabbit IgG-HRP 
conjugate. 
11) Add 50 µl of OPD solution to each well. 
a. Add one capsule of phosphate-citrate buffer to 100 ml DI in beaker and 
stir (no more than 30 min prior to use of OPD). 
b. Weigh 0.4 mg ml-1 OPD and place in foil coated tube (6.4 mg for 16 ml 
buffer). 
c. Add 40 µl of 30% H2O2 (glass fridge) to buffer. 
d. Mix for 30 sec. 
e. Add required amount of buffer to OPD (16 ml) (use within 5 min). 
f. Mix by inversion 
12) Cover the plate with adhesive cover and incubate for 30 min at room 
temperature in the dark. 




1. Combine reagents for Gibson assembly. 
a. Use 50 ng of plasmid and 0.2 pmol of each fragment (equimolar). Run 
control. 
i. 1 ul pET-30 Ek/LIC (at 50 ng/µl) 
ii. 3.3 µl F1 
iii. 3.3 µl F2 
iv. 1.7 µl F3 
b. 10 µl Gibson Master Mix (2X) 
c. Nuclease free DI (adjust to final volume of 20 µl) 
2. Incubate at 50°C for 1 h, then keep on ice (or -20°C) until transformation. 
3. Transform NEB 5-alpha competent cells (included in Gibson Assembly kit) with 
Gibson Assembly reaction product. 
a. Thaw NEB 5-alpha competent cells on ice for 2-5 min. 
b. Resuspend cells and then add 2 ul of Gibson Assembly reaction to 50 µL 
cells in transformation tube on ice. 
c. Incubate the tube on ice for 30 minutes. 
d. Heat the tube for 30 sec in 42°C water bath. 
e. Incubate tube for 2 min on ice. 
f. Add 950 µl room temperature SOC medium to tube on ice. 
g. Incubate for 60 minutes at 37°C while shaking at 250 rpm. 
h. Concurrently, heat LB agar + 35 ug l-1 kanamycin or 25 ug l-1 ampicillin 
plates to 37°C for ~20 min prior to plating. 
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i. Spread 100 µL cell solution on plates using flame/EtOH sterilized glass 
pipette at several dilutions (1:1 to 1:100) in SOC medium. Use 
kanamycin plates to select for plasmid and ampicillin plates as a control. 
j. Allow plates to sit on benchtop for several minutes, invert, and incubate 
overnight at 37°C. 
4. Using a flame sterilized, blunt glass pipet, select several colonies and culture 
each colony in 15 mL of LB medium with antibiotic at 37°C and 250 rpm for 16 
h. 
5. Collect cells through centrifugation at 1000 x g and discard supernatant. 
6. Perform a miniprep using the QIAprep spin columns. 
a. Resuspend pelleted bacterial cells in 250 ul Buffer P1 and transfer to 
microcentrifuge tube (make sure RNase A has been added to Buffer P1). 
b. Add 250 ul Buffer P2 and mix thoroughly by inverting the tube 4-6 
times. 
c. Add 350 ul Buffer N3 and mix immediately and thoroughly by inverting 
the tube 4-6 times. 
d. Centrifuge for 10 min at 13,000 rpm in microcentrifuge. 
e. Apply the supernatants from step 4 to the QIAprep spin column by 
decanting or pipetting. 
f. Centrifuge for 30-60 sec. Discard flow through. 
g. Wash QIAprep spin column by adding 0.5 mL Buffer PB and centrifuge 
for 30- 60 sec. Discard flow through. 
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h. Wash QIAprep spin column by adding 0.75 ml Buffer PE and 
centrifuging for 30-60 sec. 
i. Discard the flow through and centrifuge for an additional 1 minute to 
remove residual wash buffer. 
j. Place QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute 
DNA, add 50ul Buffer EB to the center of each QIAprep spin column, let 
stand for 1 min, then centrifuge for 1 min. 
7. Run DNA electrophoresis to select appropriate DNA plasmid to sequence. 
8. Submit for sequencing. 
a.  T7 promoter, T7 terminator, and mutant mCGL-AV sequencing primers 
were used. 
b. Plasmid DNA should be submitted at approximately 100 ng/µL and 
primers at 3-5 µM. 
9. After confirming correct sequence, transform plasmid miniprep for mutant 
mCGL-AV into T7 Express lysY competent cells and culture for expression. 
a. Thaw a tube of T7 Express lysY Competent E. coli cells on ice until the 
last ice crystals disappear (~10 min). 
b. Mix gently and carefully pipette 50 µl of cells into a transformation tube 
on ice. 
c. Add 1 µl of plasmid DNA to the cell mixture. Carefully flick the tube 4-
5 times to mix cells and DNA. Do not vortex. 
d. Place the mixture on ice for 30 min. Do not mix. 
e. Heat shock at exactly 42°C for exactly 10 sec. Do not mix. 
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f. Place on ice for 5 minutes. Do not mix. 
g. Pipette 950 µl of room temperature SOC into the mixture. 
h. Place at 37°C for 60 min. Shake vigorously at 250 rpm. 
i. Warm selection plates to 37°C for ~20 min prior to plating. 
j. Mix the cells thoroughly by flicking the tube and inverting, then perform 
multiple 10-fold serial dilutions in SOC. 
k. Spread 100 µl of each dilution onto 35 ug l-1 kanamycin plates. 
l. Allow plates to sit on benchtop for several minutes, invert, and incubate 
overnight at 37°C. 
m. Using flame sterilized, blunt glass pipet, select several colonies, and 
culture each colony in 10 mL of TB medium with 35 mg l-1 kanamycin at 
30°C with shaking at 220 rpm for 16 h. 
n. Collect colonies and 50% glycerol stocks. Store at -80°C. 
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Synthesis of AuNP-ANXA5 
Procedure: 
1. AuroVistTM-15 nm initially at 200 mg ml-1 PBS: 
a. Dilute AuNPs to (20 mg ml-1, 0.1 M) in PBS 
i. Final volume 0.5 ml 
ii. 50 ul of 200 mg ml-1 solution in 0.45 ml of PBS 
2. PEGylating AuNPs: 
a. Dilute 61.2 mg (0.36 M) HS-PEG-NH2 spacer in 0.5 ml of PBS (4:1 
weight ratio spacer:AuNPs). 
b. Sonicate spacer solution for 15 min in water bath sonicator. 
c. Add HS-PEG-NH2 solution dropwise to AuNPs solution and place on 
rotator. 
d. Let solution stir overnight on rotator (speed 1.5) at 4°C. 
3. Purifying AuNP-PEG-NH2 solution: 
a. Wash excess linker away 
i. Pipette solution into ultracentrifuge tube. Wash tube with PBS 
and place wash buffer with nanoparticles. Fill remaining 
ultracentrifuge tube space with PBS. 
ii. Centrifuge tubes at 16,000g for 20 min. 
iii. Remove supernatant and redisperse in sulfo-SMCC PBS buffer 
with water bath/probe sonicator. 
1. Add 1 mg Sulfo-SMCC in 0.5 ml PBS 
4. Adding Maleimide groups to NH2 functionalized AuNPs 
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a. Add Sulfo-SMCC solution to AuNP-PEG-NH2. 
b. Let reaction stir for 30 min under on rotator at room temperature. 
5. Purifying AuNP-SMCC solution: 
a. Wash excess crosslinker away: 
i. Pipette solution into ultracentrifuge tube. Wash tube with PBS 
and place wash buffer with nanoparticles. Fill remaining 
ultracentrifuge tube space with PBS. 
ii. Centrifuge tubes at 16,000g for 20 min. 
iii. Remove supernatant and redisperse in 0.5 ml PBS buffer with 
water bath/probe sonicator. 
6. Adding ANXA5 to maleimide functionalized AuNPs: 
a. Add 2:1 weight concentration ratio of ANXA5 to Sulfo-SMCC 
i. Annexin is 36,000 mg mmol-1 
b. Let reaction shake 18 h under moderate speed at 4°C. 
i. Vial should be stabilized in a Styrofoam box and parallel to 
ensure proper circulation. 
7. Blocking leftover Maleimide groups on AuNP-ANXA5: 
a. Dissolve 1.5mg L-Cysteine in 1mL PBS. 
i. Vortex for a minute to dissolve 
b. Add 10ul L-Cysteine solution to AuNP-ANXA5 
c. Let shake 1 h under moderate speed at 4°C. 
8. Purifying AuNP-ANXA5 solution: 
a. Wash excess Annexin away: 
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i. Pipette solution into ultracentrifuge tube. Wash tube with PBS 
and place wash buffer with nanoparticles. Fill remaining 
ultracentrifuge tube space with PBS. 
ii. Centrifuge tubes at 12,000g for 15 min. 
iii. Remove supernatant and redisperse in in desired volume of PBS 
buffer with water bath/probe sonicator. 
9. Measure concentration of AuNP and ANXA5 in final product. 
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AuNP-ANXA5 Blood Pharmacokinetics 
14) Perform retro orbital draws between 0 and 24 h in heparin tubes. 
a. Allow 20 min for clots to form before centrifugation 
b. Centrifuge at 3500g for 90 s. 
c. Remove serum with pipet and freeze (cryovial) at -80°C. 
15) Prepare biotinylated AuNP-ANXA5 nanoparticle calibration curve in 
blood/serum (typically between 0 µg ml-1 and 10 µg ml-1) and assay solutions. 
a. Diluting Buffer (1 L) 
i. 0.5 g Tween 20 (0.005%) 
ii. 2.5 g BSA (0.25%) 
iii. 1 l PBS 
b. Wash Buffer 
i. 5 g Tween 20 (0.05%) 
ii. 1 l PBS  
16) Add 50 µ of each serum sample to wells. Make appropriate dilutions. Use 
streptavidin-coated 96 well plates. 
17) Cover the plate with adhesive cover and incubate for 60 min at 37°C 
18) Shake out the plates into a sink. Wash the plates with wash buffer 4 times by 
adding 200 µ and shaking out the wash buffer into a sink. Pat plates dry by 
inverting on paper towel. 
19) Add 50 µl of Annexin V polyclonal antibody (rabbit) diluted to 1.25 µg ml-1 in 
diluting buffer to each well. 
20) Cover the plate with adhesive cover and incubate for 60 min at 37°C. 
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21) Shake out the plates into a sink. Wash the plates with wash buffer 4 times by 
adding 200 µl and shaking out the wash buffer into a sink. Pat plates dry by 
inverting on paper towel. 
22) Add 50 µl of anti-rabbit IgG-HRP conjugate (secondary antibody) diluted to 
1:1,000 (initially at about 1 mg/mL) using diluting buffer to each well. 
23) Cover the plate with adhesive cover and incubate for 60 min at 37°C. 
24) Shake out the plates into a sink. Wash the plates with wash buffer 4 times by 
adding 200 µl and shaking out the Wash buffer into a sink. Pat plates dry by 
inverting on paper towel. 
25) Add 50 µl of OPD solution to each well. 
a. Add one capsule of phosphate-citrate buffer to 100 ml DI in beaker and 
stir (no more than 30 min prior to use of OPD). 
b. Weigh 0.4 mg ml-1 OPD and place in foil coated tube (6.4 mg for 16 ml 
buffer). 
c. Add 40 µl of 30% H2O2 (glass fridge) to buffer. 
d. Mix for 30 sec. 
e. Add required amount of buffer to OPD (16 ml) (use within 5 min). 
f. Mix by inversion 
26) Cover the plate with adhesive cover and incubate for 30 min at room 
temperature in the dark. 
27) Read absorbance at 450 nm. 
